haloamino acid - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	haloamino acid	go back to main search page
Accession:	CHEBI:24470	browse the term
Definition:	Any non-proteinogenic amino acid carrying at least one halo group.
Synonyms:	related_synonym:	haloamino acids

show annotations for term's descendants Sort by:
Rat (459) Mouse (459) Human (474) Chinchilla (0) Bonobo (0) Dog (0) Squirrel (0) Pig (0) Green Monkey (0) Naked Mole-rat (0) All
Genes (459)

3,3',5'-triiodo-L-thyronine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

BCL2, apoptosis regulator

multiple interactions
increases activity

alpha-Tocopherol inhibits the reaction [Triiodothyronine, Reverse results in increased activity of BCL2 protein]

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

iodothyronine deiodinase 1

multiple interactions
increases metabolic processing

[Aurothioglucose results in decreased activity of DIO1 protein] which affects the metabolism of Triiodothyronine, Reverse; [DIO1 protein results in increased metabolism of Triiodothyronine, Reverse] which results in increased abundance of 3,3'-diiodothyronine; [Genistein results in decreased activity of DIO1 protein] which affects the metabolism of Triiodothyronine, Reverse; [Propylthiouracil results in decreased activity of DIO1 protein] which affects the metabolism of Triiodothyronine, Reverse; [xanthohumol results in decreased activity of DIO1 protein] which affects the metabolism of Triiodothyronine, Reverse; Iodoacetates inhibits the reaction [[DIO1 protein results in increased metabolism of Triiodothyronine, Reverse] which results in increased abundance of 3,3'-diiodothyronine]

PMID:21565810 PMID:25962824

NCBI chr 5:122,074,285...122,090,983
Ensembl chr 5:122,074,279...122,090,970

G

iodothyronine deiodinase 2

multiple interactions
decreases activity

benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Triiodothyronine, Reverse results in decreased activity of DIO2 protein]; Cycloheximide promotes the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Triiodothyronine, Reverse results in decreased activity of DIO2 protein]]

NCBI chr 6:109,665,523...109,679,809
Ensembl chr 6:109,665,523...109,679,809

G

insulin 1

multiple interactions

Melatonin inhibits the reaction [Triiodothyronine, Reverse inhibits the reaction [INS1 protein results in increased uptake of Glucose]]; Triiodothyronine, Reverse inhibits the reaction [INS1 protein results in increased uptake of Glucose]; Vitamin E inhibits the reaction [Triiodothyronine, Reverse inhibits the reaction [INS1 protein results in increased uptake of Glucose]]

NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536

G

nuclear receptor coactivator 2

multiple interactions

Triiodothyronine, Reverse promotes the reaction [THRA protein binds to NCOA2 protein]; Triiodothyronine, Reverse promotes the reaction [THRB protein binds to NCOA2 protein]

NCBI chr 5:5,835,642...6,069,693
Ensembl chr 5:5,835,706...6,067,451

G

nuclear factor kappa B subunit 1

multiple interactions

alpha-Tocopherol inhibits the reaction [Triiodothyronine, Reverse results in increased activity of [NFKB1 protein binds to RELA protein]]; Triiodothyronine, Reverse results in increased activity of [NFKB1 protein binds to RELA protein]

NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404

G

NFKB inhibitor alpha

increases phosphorylation
multiple interactions

Triiodothyronine, Reverse results in increased phosphorylation of NFKBIA protein
alpha-Tocopherol inhibits the reaction [Triiodothyronine, Reverse results in increased phosphorylation of NFKBIA protein]

NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941

G

natriuretic peptide B

multiple interactions
increases expression

Melatonin inhibits the reaction [Triiodothyronine, Reverse results in increased expression of NPPB mRNA]; Vitamin E affects the reaction [Triiodothyronine, Reverse results in increased expression of NPPB mRNA]

NCBI chr 5:158,416,813...158,418,175
Ensembl chr 5:158,416,866...158,418,168

G

prolyl 4-hydroxylase subunit beta

multiple interactions
affects binding

2,4-dichlorophenol inhibits the reaction [Triiodothyronine, Reverse binds to P4HB protein]; 4-nonylphenol inhibits the reaction [Triiodothyronine, Reverse binds to P4HB protein]; 4-octylphenol inhibits the reaction [Triiodothyronine, Reverse binds to P4HB protein]; bisphenol A inhibits the reaction [Triiodothyronine, Reverse binds to P4HB protein]; Pentachlorophenol inhibits the reaction [Triiodothyronine, Reverse binds to P4HB protein]; tetrabromobisphenol A inhibits the reaction [Triiodothyronine, Reverse binds to P4HB protein]; tetrachlorodian inhibits the reaction [Triiodothyronine, Reverse binds to P4HB protein]

NCBI chr10:105,836,972...105,848,583
Ensembl chr10:105,836,982...105,848,500

G

peroxisome proliferator activated receptor alpha

decreases expression

Triiodothyronine, Reverse results in decreased expression of PPARA mRNA

NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

alpha-Tocopherol inhibits the reaction [Triiodothyronine, Reverse results in increased activity of [NFKB1 protein binds to RELA protein]]; Triiodothyronine, Reverse results in increased activity of [NFKB1 protein binds to RELA protein]

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

solute carrier family 2 member 4

multiple interactions
decreases expression

Melatonin inhibits the reaction [Triiodothyronine, Reverse results in decreased expression of SLC2A4 mRNA]; Vitamin E affects the reaction [Triiodothyronine, Reverse results in decreased expression of SLC2A4 mRNA]

NCBI chr10:54,666,015...54,671,581
Ensembl chr10:54,666,015...54,671,565

G

superoxide dismutase 1

multiple interactions
decreases expression

Melatonin inhibits the reaction [Triiodothyronine, Reverse results in decreased activity of and results in decreased expression of SOD1 protein]; Melatonin inhibits the reaction [Triiodothyronine, Reverse results in decreased expression of SOD1 mRNA]; Triiodothyronine, Reverse results in decreased activity of and results in decreased expression of SOD1 protein; Vitamin E inhibits the reaction [Triiodothyronine, Reverse results in decreased activity of and results in decreased expression of SOD1 protein]; Vitamin E inhibits the reaction [Triiodothyronine, Reverse results in decreased expression of SOD1 mRNA]

NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249

G

superoxide dismutase 2

multiple interactions

alpha-Tocopherol inhibits the reaction [Triiodothyronine, Reverse results in increased expression of and results in increased activity of SOD2 protein]; Triiodothyronine, Reverse results in increased expression of and results in increased activity of SOD2 protein

NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189

G

sulfotransferase family 1A member 1

multiple interactions

Triiodothyronine, Reverse inhibits the reaction [SULT1A1 protein results in increased sulfation of 4-nitrophenol]

NCBI chr 1:181,272,022...181,276,750
Ensembl chr 1:181,272,023...181,275,562

G

thyroid hormone receptor alpha

multiple interactions

Triiodothyronine, Reverse promotes the reaction [THRA protein binds to NCOA2 protein]

NCBI chr10:83,701,885...83,729,408
Ensembl chr10:83,700,755...83,729,936

G

thyroid hormone receptor beta

increases activity
multiple interactions
affects binding

Triiodothyronine, Reverse results in increased activity of THRB protein
Triiodothyronine, Reverse promotes the reaction [THRB protein binds to NCOA2 protein]
Triiodothyronine, Reverse binds to THRB protein

PMID:21543282 PMID:31566444

NCBI chr15:7,685,180...8,031,920
Ensembl chr15:7,685,180...7,882,916

G

tumor necrosis factor

multiple interactions
increases secretion

alpha-Tocopherol inhibits the reaction [Triiodothyronine, Reverse results in increased secretion of TNF protein]

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

3,3',5'-triiodothyronine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

tumor necrosis factor

increases expression

3,3',5-triiodothyronine increases expression of Tnf protein in serum

RGD

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

3,3',5-triiodo-L-thyronine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

aminoadipate aminotransferase

decreases activity

Triiodothyronine results in decreased activity of AADAT protein

NCBI chr16:29,509,392...29,544,332
Ensembl chr16:29,509,394...29,544,332

G

ATP binding cassette subfamily A member 1

increases expression

Triiodothyronine results in increased expression of ABCA1 mRNA

NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170

G

ATP binding cassette subfamily B member 11

decreases activity
increases expression
multiple interactions

Triiodothyronine results in decreased activity of ABCB11 protein
Triiodothyronine results in increased expression of ABCB11 mRNA
[BMS201038 co-treated with Triiodothyronine] results in increased expression of ABCB11 mRNA

PMID:28437613 PMID:34902352

NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730

G

ATP binding cassette subfamily B member 4

decreases activity

Triiodothyronine results in decreased activity of ABCB4 protein

NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202

G

ATP binding cassette subfamily C member 5

increases expression

Triiodothyronine results in increased expression of ABCC5 mRNA

NCBI chr11:80,473,809...80,567,257
Ensembl chr11:80,473,872...80,567,253

G

ATP binding cassette subfamily F member 3

multiple interactions

[Triiodothyronine co-treated with Tetrachlorodibenzodioxin] results in decreased expression of ABCF3 mRNA

NCBI chr11:80,340,476...80,352,211
Ensembl chr11:80,339,977...80,352,211

G

ATP binding cassette subfamily G member 5

increases expression
multiple interactions

Triiodothyronine results in increased expression of ABCG5 mRNA
[BMS201038 co-treated with Triiodothyronine] results in increased expression of ABCG5 mRNA

NCBI chr 6:9,965,118...9,990,563
Ensembl chr 6:9,965,118...9,990,563

G

ATP binding cassette subfamily G member 8

increases expression
multiple interactions

Triiodothyronine results in increased expression of ABCG8 mRNA
[BMS201038 co-treated with Triiodothyronine] results in increased expression of ABCG8 mRNA

NCBI chr 6:9,945,629...9,964,912
Ensembl chr 6:9,945,629...9,964,912

G

acetyl-CoA carboxylase alpha

multiple interactions
increases expression
increases activity

Triiodothyronine inhibits the reaction [Streptozocin results in decreased activity of ACACA protein]; Triiodothyronine inhibits the reaction [Streptozocin results in decreased expression of ACACA mRNA]
[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA]
Triiodothyronine results in increased expression of ACACA mRNA
Triiodothyronine results in increased activity of ACACA protein

PMID:1973097 PMID:33476690

NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457

G

acyl-CoA binding domain containing 4

decreases expression

Triiodothyronine results in decreased expression of ACBD4 mRNA

NCBI chr10:88,048,058...88,062,612
Ensembl chr10:88,048,108...88,058,500

G

angiotensin I converting enzyme

multiple interactions

Triiodothyronine results in increased expression of and results in increased activity of ACE protein

NCBI chr10:90,910,316...90,930,437
Ensembl chr10:90,910,316...90,931,131

G

acyl-CoA thioesterase 1

increases expression
decreases expression

Triiodothyronine results in increased expression of ACOT1 mRNA
Triiodothyronine results in decreased expression of ACOT1 mRNA

PMID:15953391 PMID:28299817

NCBI chr 6:103,636,173...103,644,167
Ensembl chr 6:103,636,041...103,644,163

G

acyl-CoA oxidase 1

multiple interactions
increases expression

[BMS201038 co-treated with Triiodothyronine] results in increased expression of ACOX1 mRNA
Triiodothyronine results in increased expression of ACOX1 mRNA

NCBI chr10:101,406,197...101,431,252
Ensembl chr10:101,406,197...101,431,232

G

acyl-CoA synthetase long-chain family member 1

increases expression

Triiodothyronine results in increased expression of ACSL1 mRNA

NCBI chr16:45,755,246...45,821,541
Ensembl chr16:45,755,254...45,821,541

G

acyl-CoA synthetase long-chain family member 5

increases expression

Triiodothyronine results in increased expression of ACSL5 mRNA

NCBI chr 1:254,289,513...254,336,608
Ensembl chr 1:254,292,521...254,336,607

G

activin A receptor like type 1

increases expression

Triiodothyronine results in increased expression of ACVRL1 mRNA

NCBI chr 7:132,239,200...132,256,592
Ensembl chr 7:132,239,729...132,256,591

G

ADAM metallopeptidase domain 11

increases expression

Triiodothyronine results in increased expression of ADAM11 mRNA

NCBI chr10:87,724,115...87,742,773
Ensembl chr10:87,724,234...87,741,562

G

ADAM metallopeptidase domain 12

increases expression

Triiodothyronine results in increased expression of ADAM12 mRNA

NCBI chr 1:188,686,984...189,014,206
Ensembl chr 1:188,686,989...189,020,667

G

ADAM metallopeptidase domain 15

decreases expression

Triiodothyronine results in decreased expression of ADAM15 mRNA

NCBI chr 2:174,754,629...174,765,136
Ensembl chr 2:174,754,633...174,765,113

G

ADAM metallopeptidase domain 19

multiple interactions

[Triiodothyronine co-treated with Tetrachlorodibenzodioxin] results in decreased expression of ADAM19 mRNA

NCBI chr10:30,491,362...30,583,115
Ensembl chr10:30,491,405...30,583,105

G

adducin 2

increases expression

Triiodothyronine results in increased expression of ADD2 mRNA

NCBI chr 4:118,444,594...118,538,505
Ensembl chr 4:118,497,416...118,538,505

G

adiponectin, C1Q and collagen domain containing

multiple interactions

[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein]

NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564

G

adrenoceptor beta 1

increases expression

Triiodothyronine results in increased expression of ADRB1 mRNA; Triiodothyronine results in increased expression of ADRB1 protein

PMID:10217540 PMID:11090638

NCBI chr 1:255,771,962...255,774,973
Ensembl chr 1:255,771,597...255,807,259

G

adrenoceptor beta 2

multiple interactions
increases expression

bicalutamide inhibits the reaction [Triiodothyronine results in increased expression of ADRB2 protein]
Triiodothyronine results in increased expression of ADRB2 mRNA; Triiodothyronine results in increased expression of ADRB2 protein

NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512

G

adrenoceptor beta 3

multiple interactions
decreases expression
increases expression

Amiodarone inhibits the reaction [Triiodothyronine results in decreased expression of ADRB3 protein]
Triiodothyronine results in decreased expression of ADRB3 mRNA; Triiodothyronine results in decreased expression of ADRB3 protein
Triiodothyronine results in increased expression of ADRB3 protein

PMID:8836703 PMID:10217540

NCBI chr16:64,839,820...64,844,552
Ensembl chr16:64,841,788...64,844,552

G

aryl hydrocarbon receptor

multiple interactions

Triiodothyronine promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of AHR mRNA]

NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568

G

A-kinase anchoring protein 12

increases expression

Triiodothyronine results in increased expression of AKAP12 mRNA

NCBI chr 1:40,730,123...40,819,863
Ensembl chr 1:40,730,123...40,819,886

G

akirin 2

increases expression

Triiodothyronine results in increased expression of AKIRIN2 mRNA

NCBI chr 5:49,108,231...49,122,566
Ensembl chr 5:49,108,220...49,122,568

G

aldo-keto reductase family 1, member C1

increases expression

Triiodothyronine results in increased expression of AKR1C1 mRNA

NCBI chr17:65,810,474...65,837,385
Ensembl chr17:65,810,475...65,837,326

G

aldo-keto reductase family 1, member C2

increases expression

Triiodothyronine results in increased expression of AKR1C2 mRNA

NCBI chr17:65,759,778...65,808,013
Ensembl chr17:65,759,788...65,775,764

G

aldo-keto reductase family 1, member C3

increases expression

Triiodothyronine results in increased expression of AKR1C3 mRNA

NCBI chr17:66,110,970...66,127,867
Ensembl chr17:66,110,963...66,127,873

G

AKT serine/threonine kinase 1

multiple interactions
increases phosphorylation

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Triiodothyronine results in increased phosphorylation of AKT1 protein]; AKT1 protein affects the reaction [Triiodothyronine affects the expression of TTN mRNA]; Triiodothyronine inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in decreased phosphorylation of AKT1 protein]

PMID:16021636 PMID:18096819 PMID:36868496

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

albumin

affects binding

Triiodothyronine binds to ALB protein

NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836

G

aldehyde dehydrogenase 1 family, member A3

multiple interactions

[Triiodothyronine co-treated with Tetrachlorodibenzodioxin] results in increased expression of ALDH1A3 mRNA

NCBI chr 1:119,982,272...120,017,416
Ensembl chr 1:119,982,277...120,017,436

G

aldehyde dehydrogenase 3 family, member A2

increases expression

Triiodothyronine results in increased expression of ALDH3A2 mRNA

NCBI chr10:45,928,313...45,949,366
Ensembl chr10:45,908,524...45,949,281

G

anti-Mullerian hormone

multiple interactions

Triiodothyronine affects the reaction [Propylthiouracil affects the expression of AMH mRNA]

NCBI chr 7:8,906,776...8,909,192
Ensembl chr 7:8,906,836...8,909,282

G

angiopoietin-like 8

multiple interactions

[THRA protein co-treated with Triiodothyronine] promotes the reaction [ANGPTL8 protein binds to PLIN3 protein]; [THRA protein co-treated with Triiodothyronine] results in increased expression of ANGPTL8 mRNA; [THRA protein co-treated with Triiodothyronine] results in increased expression of ANGPTL8 protein; [THRB protein co-treated with Triiodothyronine] results in increased expression of ANGPTL8 mRNA; ANGPTL8 protein affects the reaction [[THRA protein co-treated with Triiodothyronine] results in decreased expression of SQSTM1 protein]

NCBI chr 8:20,376,462...20,378,488
Ensembl chr 8:20,376,462...20,378,490

G

apolipoprotein A1

increases expression

Triiodothyronine results in increased expression of APOA1 protein

NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035

G

apolipoprotein A4

multiple interactions

Triiodothyronine results in increased expression of [APOE protein co-treated with APOA4 protein]

NCBI chr 8:46,539,083...46,541,464
Ensembl chr 8:46,539,082...46,541,469

G

apolipoprotein E

multiple interactions

Triiodothyronine results in increased expression of [APOE protein co-treated with APOA4 protein]

NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932

G

amyloid beta precursor protein

decreases expression
multiple interactions

Triiodothyronine results in decreased expression of APP mRNA; Triiodothyronine results in decreased expression of APP protein
Triiodothyronine inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of APP protein modified form]
Tretinoin promotes the reaction [Triiodothyronine results in decreased secretion of APP protein]

PMID:17199430 PMID:36868496

NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561

G

aquaporin 1

increases expression

Triiodothyronine results in increased expression of AQP1 mRNA

NCBI chr 4:84,482,512...84,494,690
Ensembl chr 4:84,482,512...84,494,690

G

aquaporin 8

increases expression

Triiodothyronine results in increased expression of AQP8 mRNA

NCBI chr 1:177,993,313...177,999,158
Ensembl chr 1:177,993,305...177,999,158

G

androgen receptor

multiple interactions

Triiodothyronine inhibits the reaction [[6-fluorotestosterone co-treated with Norgestrel] binds to and results in increased activity of AR protein]

NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925

G

Rho guanine nucleotide exchange factor 25

decreases expression

Triiodothyronine results in decreased expression of ARHGEF25 mRNA

NCBI chr 7:63,005,938...63,013,325
Ensembl chr 7:63,005,940...63,013,719

G

ARF like GTPase 4D

increases expression

Triiodothyronine results in increased expression of ARL4D mRNA

NCBI chr10:86,592,054...86,602,843
Ensembl chr10:86,595,661...86,602,836

G

arrestin domain containing 3

increases expression

Triiodothyronine results in increased expression of ARRDC3 mRNA

NCBI chr 2:11,137,464...11,149,978
Ensembl chr 2:11,137,460...11,149,978

G

asparaginase

increases expression

Triiodothyronine results in increased expression of ASPG mRNA

NCBI chr 6:131,176,727...131,196,268
Ensembl chr 6:131,176,874...131,196,268

G

assembly factor for spindle microtubules

decreases expression

Triiodothyronine results in decreased expression of ASPM mRNA

NCBI chr13:51,074,849...51,123,755
Ensembl chr13:51,074,849...51,123,755

G

autophagy related 5

increases expression
affects response to substance

Triiodothyronine results in increased expression of ATG5 mRNA; Triiodothyronine results in increased expression of ATG5 protein
ATG5 protein affects the susceptibility to Triiodothyronine

NCBI chr20:47,798,217...47,889,216
Ensembl chr20:47,798,290...47,889,209

G

autophagy related 7

increases expression

Triiodothyronine results in increased expression of ATG7 mRNA

NCBI chr 4:147,718,663...147,925,656
Ensembl chr 4:147,718,752...147,925,593

G

ATPase Na+/K+ transporting subunit beta 2

increases expression

Triiodothyronine results in increased expression of ATP1B2 mRNA

NCBI chr10:54,318,698...54,324,933
Ensembl chr10:54,318,701...54,324,933

G

ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2

multiple interactions
increases expression

THRB protein promotes the reaction [Triiodothyronine results in increased expression of ATP2A2 mRNA]; Triiodothyronine inhibits the reaction [Phenylephrine results in decreased expression of ATP2A2 mRNA]

NCBI chr12:34,072,710...34,122,142
Ensembl chr12:34,072,683...34,122,101

G

arginine vasopressin

multiple interactions

[AVP protein co-treated with Norepinephrine] inhibits the reaction [Triiodothyronine inhibits the reaction [EGF protein results in decreased expression of UCP1 mRNA]]; [AVP protein co-treated with Norepinephrine] inhibits the reaction [Triiodothyronine promotes the reaction [FGF1 protein results in increased expression of UCP1 mRNA]]; [AVP protein co-treated with Norepinephrine] inhibits the reaction [Triiodothyronine promotes the reaction [FGF2 protein results in increased expression of UCP1 mRNA]]; [AVP protein co-treated with Norepinephrine] inhibits the reaction [Triiodothyronine results in increased expression of UCP1 mRNA]; [EGF protein co-treated with AVP protein co-treated with Norepinephrine co-treated with Triiodothyronine] results in decreased expression of UCP1 mRNA; [FGF1 protein co-treated with AVP protein co-treated with Norepinephrine co-treated with Triiodothyronine] results in decreased expression of UCP1 mRNA; AVP protein inhibits the reaction [Triiodothyronine inhibits the reaction [EGF protein results in decreased expression of UCP1 mRNA]]; AVP protein inhibits the reaction [Triiodothyronine promotes the reaction [FGF1 protein results in increased expression of UCP1 mRNA]]; AVP protein inhibits the reaction [Triiodothyronine promotes the reaction [FGF2 protein results in increased expression of UCP1 mRNA]]; AVP protein inhibits the reaction [Triiodothyronine results in increased expression of UCP1 mRNA]

NCBI chr 3:117,793,447...117,805,091
Ensembl chr 3:117,793,457...117,795,425

G

beta-secretase 1

multiple interactions

Triiodothyronine inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of BACE1 protein]

NCBI chr 8:46,142,060...46,166,268
Ensembl chr 8:46,142,116...46,165,876

G

BCL2-associated agonist of cell death

decreases expression

Triiodothyronine results in decreased expression of BAD protein

NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823

G

BCL2 associated X, apoptosis regulator

decreases expression

Triiodothyronine results in decreased expression of BAX protein

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

BCL2, apoptosis regulator

multiple interactions
increases expression

Triiodothyronine promotes the reaction [tamibarotene results in decreased expression of BCL2 mRNA]
Triiodothyronine results in increased expression of BCL2 protein

PMID:11201846 PMID:16021636

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

BCL2-related protein A1

multiple interactions

Triiodothyronine promotes the reaction [tamibarotene results in increased expression of BCL2A1A mRNA]

NCBI chr 8:89,716,914...89,724,998
Ensembl chr 8:89,716,914...89,724,998

G

Bcl2-like 1

increases expression

Triiodothyronine results in increased expression of BCL2L1 protein

NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479

G

BCL3, transcription coactivator

increases expression

Triiodothyronine results in increased expression of BCL3 mRNA

NCBI chr 1:79,471,368...79,485,908
Ensembl chr 1:79,471,369...79,485,607

G

bone morphogenetic protein 2

multiple interactions

[Triiodothyronine co-treated with Tetrachlorodibenzodioxin] results in decreased expression of BMP2 mRNA

NCBI chr 3:120,812,660...120,822,579
Ensembl chr 3:120,812,882...120,821,397

G

bone morphogenetic protein 6

multiple interactions
decreases expression

4-OH-2',3,3',4',5'-pentachlorobiphenyl inhibits the reaction [Triiodothyronine results in decreased expression of BMP6 mRNA]; Polychlorinated Biphenyls inhibits the reaction [Triiodothyronine results in decreased expression of BMP6 mRNA]; Tetrachlorodibenzodioxin promotes the reaction [Triiodothyronine results in decreased expression of BMP6 mRNA]

NCBI chr17:26,318,121...26,469,691
Ensembl chr17:26,318,569...26,470,365

G

bone morphogenetic protein 7

multiple interactions

[BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of CS mRNA; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of HGF mRNA; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of MMP2 mRNA; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of PPARGC1A mRNA; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of PPARGC1A protein; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of PRDM16 mRNA; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of UCP1 mRNA; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of UCP1 protein; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of VEGFA mRNA

NCBI chr 3:161,639,915...161,716,938
Ensembl chr 3:161,516,462...161,716,788

G

calpain, small subunit 1

multiple interactions

[Triiodothyronine co-treated with Tetrachlorodibenzodioxin] results in increased expression of CAPNS1 mRNA

NCBI chr 1:85,444,613...85,454,861
Ensembl chr 1:85,444,608...85,454,795

G

caspase 3

decreases expression
multiple interactions

Triiodothyronine results in decreased expression of CASP3 protein
THRA protein affects the reaction [Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased cleavage of CASP3 protein]]; THRA protein affects the reaction [Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased expression of CASP3 mRNA]]; Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased cleavage of CASP3 protein]; Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased expression of CASP3 mRNA]

PMID:16021636 PMID:32223187

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

catalase

multiple interactions
decreases activity

[Triiodothyronine co-treated with Hexachlorocyclohexane] results in decreased activity of CAT protein; gadolinium chloride inhibits the reaction [[Triiodothyronine co-treated with Hexachlorocyclohexane] results in decreased activity of CAT protein]; Resveratrol inhibits the reaction [Triiodothyronine results in decreased activity of CAT protein]

PMID:12516873 PMID:23391542

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

coiled-coil domain containing 71

decreases expression

Triiodothyronine results in decreased expression of CCDC71 mRNA

NCBI chr 8:109,146,650...109,161,749
Ensembl chr 8:109,146,359...109,165,216

G

C-C motif chemokine ligand 5

multiple interactions
increases expression

4-OH-2',3,3',4',5'-pentachlorobiphenyl inhibits the reaction [Triiodothyronine results in increased expression of CCL5 mRNA]; Polychlorinated Biphenyls inhibits the reaction [Triiodothyronine results in increased expression of CCL5 mRNA]; Tetrachlorodibenzodioxin promotes the reaction [Triiodothyronine results in increased expression of CCL5 mRNA]

NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377

G

cyclin A2

increases expression

Triiodothyronine results in increased expression of CCNA2 protein

NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577

G

cyclin D1

increases expression
multiple interactions

Triiodothyronine results in increased expression of CCND1 protein
Triiodothyronine results in increased expression of CCND1 mRNA; Triiodothyronine results in increased expression of CCND1 protein
THRB protein promotes the reaction [Triiodothyronine results in increased expression of CCND1 protein]; U 0126 inhibits the reaction [Triiodothyronine results in increased expression of CCND1 mRNA]

PMID:16021636 PMID:20638743 PMID:28315333

NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602

G

cyclin E1

increases expression

Triiodothyronine results in increased expression of CCNE1 protein
Triiodothyronine results in increased expression of CCNE1 mRNA; Triiodothyronine results in increased expression of CCNE1 protein

NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101

G

cell division cycle 45

multiple interactions

[Triiodothyronine co-treated with Tetrachlorodibenzodioxin] results in decreased expression of CDC45 mRNA

NCBI chr11:82,185,427...82,210,630
Ensembl chr11:82,185,473...82,210,619

G

cyclin-dependent kinase inhibitor 1A

multiple interactions
increases expression

[Triiodothyronine co-treated with Tetrachlorodibenzodioxin] results in increased expression of CDKN1A mRNA; Tetrachlorodibenzodioxin promotes the reaction [Triiodothyronine results in increased expression of CDKN1A mRNA]; Triiodothyronine analog inhibits the reaction [CDKN1A protein binds to PCNA protein]; Triiodothyronine inhibits the reaction [CDKN1A protein binds to PCNA protein]

PMID:14761676 PMID:22383522

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

G

cyclin-dependent kinase inhibitor 1B

decreases expression
multiple interactions

Triiodothyronine results in decreased expression of CDKN1B mRNA; Triiodothyronine results in decreased expression of CDKN1B protein
THRB protein promotes the reaction [Triiodothyronine results in decreased expression of CDKN1B protein]

PMID:16021636 PMID:20638743

NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982

G

CCAAT/enhancer binding protein alpha

multiple interactions

[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein; Orlistat promotes the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein]; Rosmarinic Acid affects the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein]

NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412

G

centrosomal protein 15

increases expression

Triiodothyronine results in increased expression of CEP15 mRNA

NCBI chr15:12,815,159...12,835,115
Ensembl chr15:12,818,385...12,833,838

G

carboxylesterase 2C

increases expression

Triiodothyronine results in increased expression of CES2C mRNA

NCBI chr 1:260,391,190...260,398,757
Ensembl chr 1:260,388,902...260,398,790

G

glycoprotein hormones, alpha polypeptide

multiple interactions
decreases expression

Phenelzine inhibits the reaction [Triiodothyronine results in decreased expression of CGA mRNA]; Triiodothyronine inhibits the reaction [Phenelzine results in increased expression of CGA mRNA]

NCBI chr 5:49,486,915...49,499,192
Ensembl chr 5:49,487,068...49,499,191

G

checkpoint kinase 1

increases phosphorylation

Triiodothyronine analog results in increased phosphorylation of CHEK1 protein

NCBI chr 8:36,420,565...36,443,477
Ensembl chr 8:36,420,569...36,441,009

G

carbohydrate sulfotransferase 1

increases expression

Triiodothyronine results in increased expression of CHST1 mRNA

NCBI chr 3:78,552,059...78,574,740
Ensembl chr 3:78,548,525...78,574,883

G

clusterin

increases expression

Triiodothyronine results in increased expression of CLU mRNA

NCBI chr15:40,161,068...40,200,315
Ensembl chr15:40,174,617...40,200,315

G

collagen type X alpha 1 chain

multiple interactions
increases expression

ciglitazone inhibits the reaction [Triiodothyronine results in increased expression of COL10A1 mRNA]; troglitazone inhibits the reaction [Triiodothyronine results in increased expression of COL10A1 mRNA]

NCBI chr20:38,183,103...38,189,488
Ensembl chr20:38,182,494...38,189,494

G

collagen type I alpha 1 chain

multiple interactions
increases expression

Triiodothyronine promotes the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA]
Triiodothyronine results in increased expression of COL1A1 mRNA

NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624

G

collagen type VI alpha 3 chain

increases expression

Triiodothyronine results in increased expression of COL6A3 mRNA

NCBI chr 9:91,361,578...91,439,434
Ensembl chr 9:91,361,583...91,439,471

G

coenzyme Q10B

increases expression

Triiodothyronine results in increased expression of COQ10B mRNA

NCBI chr 9:56,553,751...56,573,671
Ensembl chr 9:56,553,758...56,573,663

G

cytochrome c oxidase subunit 4i1

multiple interactions
increases expression

Chloroquine promotes the reaction [Triiodothyronine results in increased expression of COX4I1 protein]

NCBI chr19:48,721,680...48,727,920
Ensembl chr19:48,721,199...48,727,921

G

carnitine palmitoyltransferase 1A

increases expression
multiple interactions

Triiodothyronine results in increased expression of CPT1A mRNA
Triiodothyronine results in increased expression of CPT1A mRNA; Triiodothyronine results in increased expression of CPT1A protein
resveratrol promotes the reaction [Triiodothyronine results in increased expression of CPT1A mRNA]
[BMS201038 co-treated with Triiodothyronine] results in increased expression of CPT1A mRNA; Resveratrol promotes the reaction [Triiodothyronine results in increased expression of CPT1A mRNA]; SIRT1 protein affects the reaction [Triiodothyronine results in increased expression of CPT1A mRNA]; SIRT1 protein affects the reaction [Triiodothyronine results in increased expression of CPT1A protein]; Triiodothyronine promotes the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of CPT1A mRNA]

PMID:23209300 PMID:25048947 PMID:34902352

NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055

G

carnitine palmitoyltransferase 1B

increases expression

Triiodothyronine results in increased expression of CPT1B mRNA

NCBI chr 7:120,491,354...120,500,833
Ensembl chr 7:120,491,354...120,500,404

G

calcium release activated channel regulator 2B

decreases expression

Triiodothyronine results in decreased expression of CRACR2B mRNA

NCBI chr 1:196,558,407...196,563,961
Ensembl chr 1:196,558,588...196,563,771

G

carnitine O-acetyltransferase

increases expression

Triiodothyronine results in increased expression of CRAT mRNA

NCBI chr 3:13,675,684...13,689,282
Ensembl chr 3:13,675,684...13,689,255

G

citrate synthase

multiple interactions
decreases activity

[BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of CS mRNA
Triiodothyronine results in decreased activity of CS protein

PMID:1153425 PMID:33091441

NCBI chr 7:758,074...791,421
Ensembl chr 7:758,345...791,421

G

cysteine sulfinic acid decarboxylase

increases expression

Triiodothyronine results in increased expression of CSAD mRNA

NCBI chr 7:133,308,571...133,337,914
Ensembl chr 7:133,308,574...133,337,615

G

C-terminal Src kinase

multiple interactions

CSK protein promotes the reaction [Tetrachlorodibenzodioxin promotes the reaction [Triiodothyronine binds to THRA protein]]

NCBI chr 8:58,029,748...58,048,742
Ensembl chr 8:58,029,749...58,048,292

G

cathepsin E

increases expression

Triiodothyronine results in increased expression of CTSE mRNA

NCBI chr13:43,091,954...43,114,509
Ensembl chr13:43,092,128...43,114,502

G

cytochrome c, somatic

multiple interactions

THRA protein affects the reaction [Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased expression of CYCS mRNA]]; Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased expression of CYCS mRNA]

NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054
Ensembl chr18:79,651,378...79,654,054

G

cytochrome P450, family 11, subfamily a, polypeptide 1

multiple interactions

2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [Triiodothyronine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 mRNA]]; 2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [Triiodothyronine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 protein]]; Triiodothyronine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 mRNA]; Triiodothyronine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 protein]

NCBI chr 8:58,422,807...58,434,342
Ensembl chr 8:58,404,669...58,434,338

G

cytochrome P450, family 17, subfamily a, polypeptide 1

multiple interactions

2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [Triiodothyronine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP17A1 mRNA]]; 2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [Triiodothyronine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP17A1 protein]]; Triiodothyronine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP17A1 mRNA]; Triiodothyronine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP17A1 protein]

NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573

G

cytochrome P450, family 19, subfamily a, polypeptide 1

multiple interactions
increases expression

Chlorpyrifos inhibits the reaction [Triiodothyronine results in increased expression of CYP19A1 mRNA]; Ethylenethiourea inhibits the reaction [Triiodothyronine results in increased expression of CYP19A1 mRNA]

NCBI chr 8:54,552,978...54,580,375
Ensembl chr 8:54,553,165...54,580,758

G

cytochrome P450, family 1, subfamily a, polypeptide 1

multiple interactions
increases expression

Triiodothyronine affects the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]; Triiodothyronine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 protein]
Triiodothyronine results in increased expression of CYP1A1 mRNA

NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125

G

cytochrome P450, family 1, subfamily a, polypeptide 2

increases expression
multiple interactions

Triiodothyronine results in increased expression of CYP1A2 mRNA
Triiodothyronine affects the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A2 mRNA]; Triiodothyronine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A2 protein]

NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312

G

cytochrome P450, family 24, subfamily a, polypeptide 1

increases expression
multiple interactions

Triiodothyronine results in increased expression of CYP24A1 mRNA
(4-(4-hydroxy-3-isopropyl-5-(4-nitrophenylethynyl)benzyl)-3,5-dimethylphenoxy)acetic acid inhibits the reaction [Triiodothyronine results in increased expression of CYP24A1 mRNA]

NCBI chr 3:159,275,947...159,290,383
Ensembl chr 3:159,275,947...159,290,383

G

cytochrome P450, family 2, subfamily e, polypeptide 1

increases activity
increases expression

Triiodothyronine results in increased activity of CYP2E1 protein
Triiodothyronine results in increased expression of CYP2E1 protein

NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023

G

cytochrome P450, family 3, subfamily a, polypeptide 2

increases expression
multiple interactions

Triiodothyronine results in increased expression of CYP3A4 mRNA
SJ 000311413 inhibits the reaction [Triiodothyronine results in increased expression of CYP3A4 mRNA]

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

G

cytochrome P450 family 8 subfamily B member 1

decreases expression

Triiodothyronine results in decreased expression of CYP8B1 mRNA

PMID:10393316 PMID:29357290

NCBI chr 8:121,578,123...121,580,093
Ensembl chr 8:121,557,062...121,580,166

G

D-box binding PAR bZIP transcription factor

increases expression

Triiodothyronine results in increased expression of DBP mRNA

NCBI chr 1:96,175,796...96,180,745
Ensembl chr 1:96,175,440...96,180,745

G

2,4-dienoyl-CoA reductase 2

increases expression

Triiodothyronine results in increased expression of DECR2 mRNA

NCBI chr10:15,104,907...15,113,281
Ensembl chr10:15,002,926...15,118,479

G

iodothyronine deiodinase 1

affects abundance
multiple interactions
increases expression
affects metabolic processing
increases chemical synthesis

DIO1 gene SNP affects the abundance of Triiodothyronine
2,2',4,4'-tetrabromodiphenyl ether inhibits the reaction [Triiodothyronine results in increased expression of DIO1 mRNA]
[DIO1 protein co-treated with DIO2 protein co-treated with DIO3 protein] affects the abundance of Triiodothyronine; [DIO1 protein results in increased metabolism of Thyroxine] which results in increased abundance of Triiodothyronine; Iodoacetates inhibits the reaction [[DIO1 protein results in increased metabolism of Thyroxine] which results in increased abundance of Triiodothyronine]
DIO1 protein affects the metabolism of Triiodothyronine
Arsenic affects the reaction [Triiodothyronine results in increased expression of DIO1 mRNA]; Pentachlorophenol inhibits the reaction [Triiodothyronine results in increased expression of DIO1 mRNA]
DIO1 protein results in increased chemical synthesis of Triiodothyronine

PMID:15254343 PMID:16131326 PMID:17105838 PMID:18288313 PMID:21565810 More...

NCBI chr 5:122,074,285...122,090,983
Ensembl chr 5:122,074,279...122,090,970

G

iodothyronine deiodinase 2

multiple interactions
decreases expression
increases expression
increases chemical synthesis

2,2',4,4',5-brominated diphenyl ether inhibits the reaction [[DIO2 protein results in increased metabolism of Thyroxine] which results in increased chemical synthesis of Triiodothyronine]; 2,2',4,4',5-brominated diphenyl ether metabolite inhibits the reaction [[DIO2 protein results in increased metabolism of Thyroxine] which results in increased chemical synthesis of Triiodothyronine]; 2,2',4,4'-tetrabromodiphenyl ether metabolite inhibits the reaction [[DIO2 protein results in increased metabolism of Thyroxine] which results in increased chemical synthesis of Triiodothyronine]; [DIO1 protein co-treated with DIO2 protein co-treated with DIO3 protein] affects the abundance of Triiodothyronine; [DIO2 protein results in increased metabolism of Thyroxine] which results in increased chemical synthesis of Triiodothyronine; kaempferol promotes the reaction [DIO2 protein results in increased activity of and results in increased abundance of Triiodothyronine]
Triiodothyronine results in decreased expression of DIO2 mRNA
[Chlorpyrifos co-treated with Triiodothyronine] results in decreased expression of DIO2 mRNA; [Ethylenethiourea co-treated with Triiodothyronine] results in decreased expression of DIO2 mRNA
Triiodothyronine results in increased expression of DIO2 mRNA
DIO2 protein results in increased chemical synthesis of Triiodothyronine

PMID:17327447 PMID:17615150 PMID:23397585 PMID:25646720 PMID:26004626 More...

NCBI chr 6:109,665,523...109,679,809
Ensembl chr 6:109,665,523...109,679,809

G

iodothyronine deiodinase 3

increases expression
multiple interactions

Triiodothyronine results in increased expression of DIO3 mRNA
Ethylenethiourea inhibits the reaction [Triiodothyronine results in increased expression of DIO3 mRNA]
[Aurothioglucose results in decreased activity of DIO3 protein] which affects the metabolism of Triiodothyronine; [DIO1 protein co-treated with DIO2 protein co-treated with DIO3 protein] affects the abundance of Triiodothyronine; [xanthohumol results in decreased activity of DIO3 protein] which affects the metabolism of Triiodothyronine

PMID:23397585 PMID:25962824 PMID:34571837

NCBI chr 6:129,285,747...129,287,608
Ensembl chr 6:129,285,749...129,286,660

G

distal-less homeobox 2

multiple interactions

[pyriproxyfen metabolite co-treated with Triiodothyronine] results in increased expression of DLX2 mRNA

NCBI chr 3:56,370,238...56,373,581
Ensembl chr 3:56,370,483...56,373,597

G

deleted in malignant brain tumors 1

multiple interactions

[Triiodothyronine co-treated with Tetrachlorodibenzodioxin] results in decreased expression of DMBT1 mRNA

NCBI chr 1:185,617,469...185,696,476
Ensembl chr 1:185,617,294...185,696,478

G

DM1 protein kinase

increases expression

Triiodothyronine results in increased expression of DMPK mRNA

NCBI chr 1:78,730,255...78,740,585
Ensembl chr 1:78,730,275...78,740,593

G

dematin actin binding protein

increases expression

Triiodothyronine results in increased expression of DMTN mRNA

NCBI chr15:45,677,974...45,702,261
Ensembl chr15:45,677,977...45,705,601

G

dual specificity phosphatase 2

multiple interactions
decreases expression

[Triiodothyronine co-treated with Tetrachlorodibenzodioxin] results in decreased expression of DUSP2 mRNA; Tetrachlorodibenzodioxin promotes the reaction [Triiodothyronine results in decreased expression of DUSP2 mRNA]

NCBI chr 3:114,556,325...114,558,510
Ensembl chr 3:114,556,325...114,558,499

G

dynein, cytoplasmic 1 light intermediate chain 2

increases expression

Triiodothyronine results in increased expression of DYNC1LI2 mRNA

NCBI chr19:531,783...554,670
Ensembl chr19:531,812...554,670

G

enoyl-CoA hydratase 1

increases expression

Triiodothyronine results in increased expression of ECH1 mRNA

NCBI chr 1:84,114,494...84,120,788
Ensembl chr 1:84,112,751...84,120,795

G

EF-hand calcium binding domain 3

decreases expression

Triiodothyronine results in decreased expression of EFCAB3 mRNA

NCBI chr10:89,583,526...90,077,260
Ensembl chr10:89,644,522...90,077,259

G

epidermal growth factor

multiple interactions

[AVP protein co-treated with Norepinephrine] inhibits the reaction [Triiodothyronine inhibits the reaction [EGF protein results in decreased expression of UCP1 mRNA]]; [EGF protein co-treated with AVP protein co-treated with Norepinephrine co-treated with Triiodothyronine] results in decreased expression of UCP1 mRNA; AVP protein inhibits the reaction [Triiodothyronine inhibits the reaction [EGF protein results in decreased expression of UCP1 mRNA]]; Triiodothyronine inhibits the reaction [EGF protein results in decreased expression of UCP1 mRNA]
Triiodothyronine inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; Triiodothyronine inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]

PMID:11742803 PMID:16150908

NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064

G

eukaryotic translation initiation factor 4E binding protein 1

decreases phosphorylation

Triiodothyronine results in decreased phosphorylation of EIF4EBP1 protein

NCBI chr16:64,792,595...64,805,984
Ensembl chr16:64,790,226...64,805,984

G

EMAP like 2

increases expression

Triiodothyronine results in increased expression of EML2 mRNA

NCBI chr 1:78,827,595...78,859,342
Ensembl chr 1:78,828,080...78,859,341

G

enolase 1

increases expression

Triiodothyronine results in increased expression of ENO1 mRNA

NCBI chr 5:160,719,951...160,731,337
Ensembl chr 5:160,719,951...160,731,336

G

endothelial PAS domain protein 1

increases expression

Triiodothyronine results in increased expression of EPAS1 mRNA

NCBI chr 6:7,790,236...7,871,717
Ensembl chr 6:7,790,647...7,871,228

G

erythrocyte membrane protein band 4.1-like 3

multiple interactions

[Triiodothyronine co-treated with Tetrachlorodibenzodioxin] results in decreased expression of EPB41L3 mRNA

NCBI chr 9:109,056,178...109,260,607
Ensembl chr 9:109,016,113...109,260,607

G

epiregulin

increases expression

Triiodothyronine results in increased expression of EREG mRNA

NCBI chr14:17,027,287...17,041,062
Ensembl chr14:17,027,287...17,041,062

G

estrogen receptor 1

multiple interactions
increases expression
decreases expression

Tamoxifen inhibits the reaction [Triiodothyronine results in decreased expression of ESR1 mRNA]; Triiodothyronine binds to and results in increased activity of ESR1 protein
[Chlorpyrifos co-treated with Triiodothyronine] results in increased expression of ESR1 mRNA; Ethylenethiourea inhibits the reaction [Triiodothyronine results in increased expression of ESR1 mRNA]

PMID:19942988 PMID:33049310 PMID:34571837

NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002

G

estrogen receptor 2

multiple interactions

[Arsenic co-treated with Estradiol co-treated with Triiodothyronine] results in decreased expression of ESR2 mRNA; [bisphenol A co-treated with Estradiol co-treated with Triiodothyronine] results in increased expression of ESR2 mRNA; [bisphenol A co-treated with Zearalenone co-treated with Arsenic co-treated with enzacamene co-treated with Estradiol co-treated with Triiodothyronine] results in decreased expression of ESR2 mRNA; [bisphenol A results in increased susceptibility to [Estradiol co-treated with Triiodothyronine]] which results in increased expression of ESR2 mRNA; [enzacamene co-treated with Estradiol co-treated with Triiodothyronine] affects the expression of ESR2 mRNA; [Estradiol co-treated with Triiodothyronine] inhibits the reaction [bisphenol A results in decreased expression of ESR2 mRNA]; [Estradiol co-treated with Triiodothyronine] promotes the reaction [Zearalenone results in decreased expression of ESR2 mRNA]; [Zearalenone co-treated with Estradiol co-treated with Triiodothyronine] results in decreased expression of ESR2 mRNA; [Zearalenone results in increased susceptibility to [Estradiol co-treated with Triiodothyronine]] which results in decreased expression of ESR2 mRNA
Triiodothyronine binds to and results in increased activity of ESR2 protein

PMID:27338438 PMID:33049310

NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919

G

ETHE1, persulfide dioxygenase

increases expression

Triiodothyronine results in increased expression of ETHE1 mRNA

NCBI chr 1:80,184,037...80,199,092
Ensembl chr 1:80,183,894...80,199,052

G

eva-1 homolog C

increases expression

Triiodothyronine results in increased expression of EVA1C mRNA

NCBI chr11:30,089,510...30,163,596
Ensembl chr11:30,089,365...30,163,596

G

fatty acid binding protein 4

increases expression
multiple interactions

Triiodothyronine results in increased expression of FABP4 mRNA
[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FABP4 mRNA; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FABP4 mRNA]

PMID:15953391 PMID:33476690

NCBI chr 2:91,580,879...91,585,567
Ensembl chr 2:91,580,885...91,585,578

G

fatty acid binding protein 5

increases expression

Triiodothyronine results in increased expression of FABP5 mRNA

NCBI chr 2:91,765,056...91,768,716
Ensembl chr 2:91,765,056...91,853,773

G

fatty acid desaturase 2

increases expression

Triiodothyronine results in increased expression of FADS2 mRNA

NCBI chr 1:206,707,384...206,747,333
Ensembl chr 1:206,708,783...206,748,789

G

family with sequence similarity 171, member B

decreases expression

Triiodothyronine results in decreased expression of FAM171B mRNA

NCBI chr 3:68,930,755...68,986,113
Ensembl chr 3:68,930,822...68,986,127

G

family with sequence similarity 83, member H

increases expression

Triiodothyronine results in increased expression of FAM83H mRNA

NCBI chr 7:107,716,431...107,724,619
Ensembl chr 7:107,716,431...107,728,672

G

fatty acid synthase

increases expression
multiple interactions

Triiodothyronine results in increased expression of FASN mRNA
[pyriproxyfen metabolite co-treated with Triiodothyronine] results in increased expression of FASN mRNA
[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA]

PMID:15953391 PMID:33476690 PMID:34289950

NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261

G

farnesyl diphosphate farnesyl transferase 1

increases expression

Triiodothyronine results in increased expression of FDFT1 mRNA

NCBI chr15:37,412,143...37,440,198
Ensembl chr15:37,412,146...37,440,287

G

farnesyl diphosphate synthase

increases expression

Triiodothyronine results in increased expression of FDPS mRNA

NCBI chr 2:174,497,402...174,507,031
Ensembl chr 2:174,486,665...174,507,776

G

fibroblast growth factor 1

multiple interactions

[AVP protein co-treated with Norepinephrine] inhibits the reaction [Triiodothyronine promotes the reaction [FGF1 protein results in increased expression of UCP1 mRNA]]; [FGF1 protein co-treated with AVP protein co-treated with Norepinephrine co-treated with Triiodothyronine] results in decreased expression of UCP1 mRNA; AVP protein inhibits the reaction [Triiodothyronine promotes the reaction [FGF1 protein results in increased expression of UCP1 mRNA]]; Triiodothyronine promotes the reaction [FGF1 protein results in increased expression of UCP1 mRNA]

NCBI chr18:30,686,555...30,772,667
Ensembl chr18:30,686,581...30,772,357

G

fibroblast growth factor 18

multiple interactions

Triiodothyronine promotes the reaction [FGF18 protein results in increased phosphorylation of MAPK1 protein]; Triiodothyronine promotes the reaction [FGF18 protein results in increased phosphorylation of MAPK3 protein]

NCBI chr10:17,706,011...17,737,702
Ensembl chr10:17,706,174...17,736,818

G

fibroblast growth factor 2

multiple interactions

Triiodothyronine inhibits the reaction [FGF2 protein results in increased phosphorylation of STAT1 protein]; Triiodothyronine promotes the reaction [FGF2 protein results in increased phosphorylation of MAPK1 protein]; Triiodothyronine promotes the reaction [FGF2 protein results in increased phosphorylation of MAPK3 protein]
[AVP protein co-treated with Norepinephrine] inhibits the reaction [Triiodothyronine promotes the reaction [FGF2 protein results in increased expression of UCP1 mRNA]]; AVP protein inhibits the reaction [Triiodothyronine promotes the reaction [FGF2 protein results in increased expression of UCP1 mRNA]]; Triiodothyronine promotes the reaction [FGF2 protein promotes the reaction [FGFR1 protein results in increased phosphorylation of FGFR1 protein]]; Triiodothyronine promotes the reaction [FGF2 protein results in increased expression of UCP1 mRNA]; Triiodothyronine promotes the reaction [FGF2 protein results in increased phosphorylation of and results in increased activity of MAPK1 protein]; Triiodothyronine promotes the reaction [FGF2 protein results in increased phosphorylation of and results in increased activity of MAPK3 protein]

PMID:11742803 PMID:12805413 PMID:16150908

NCBI chr 2:120,236,328...120,290,673
Ensembl chr 2:120,236,328...120,291,221

G

fibroblast growth factor 7

decreases expression

Triiodothyronine results in decreased expression of FGF7 mRNA

NCBI chr 3:113,280,448...113,333,279
Ensembl chr 3:113,281,283...113,332,929

G

fibroblast growth factor 9

multiple interactions

Triiodothyronine promotes the reaction [FGF9 protein results in increased phosphorylation of MAPK1 protein]; Triiodothyronine promotes the reaction [FGF9 protein results in increased phosphorylation of MAPK3 protein]

NCBI chr15:32,208,993...32,254,952
Ensembl chr15:32,210,074...32,253,309

G

Fibroblast growth factor receptor 1

increases expression
multiple interactions

Triiodothyronine results in increased expression of FGFR1 mRNA
Triiodothyronine results in increased expression of FGFR1 mRNA; Triiodothyronine results in increased expression of FGFR1 protein
Cycloheximide inhibits the reaction [Triiodothyronine results in increased expression of FGFR1 mRNA]; Dactinomycin inhibits the reaction [Triiodothyronine results in increased expression of FGFR1 mRNA]; Triiodothyronine promotes the reaction [FGF2 protein promotes the reaction [FGFR1 protein results in increased phosphorylation of FGFR1 protein]]

PMID:12805413 PMID:16150908

NCBI chr16:66,491,930...66,547,161
Ensembl chr16:66,494,042...66,547,350

G

fibroblast growth factor receptor 2

increases expression

Triiodothyronine results in increased expression of FGFR2 mRNA

NCBI chr 1:184,745,418...184,850,655
Ensembl chr 1:184,745,420...184,850,626

G

fibroblast growth factor receptor 3

increases expression

Triiodothyronine results in increased expression of FGFR3 mRNA

NCBI chr14:76,987,242...77,002,671
Ensembl chr14:76,987,993...77,003,341

G

FKBP prolyl isomerase 10

decreases expression

Triiodothyronine results in decreased expression of FKBP10 mRNA

NCBI chr10:85,345,434...85,357,998
Ensembl chr10:85,346,126...85,427,330

G

fibronectin leucine rich transmembrane protein 1

increases expression

Triiodothyronine results in increased expression of FLRT1 mRNA

NCBI chr 1:204,275,785...204,292,844
Ensembl chr 1:204,275,367...204,353,750

G

forkhead box O6

increases expression

Triiodothyronine results in increased expression of FOXO6 mRNA

NCBI chr 5:133,856,087...133,876,387
Ensembl chr 5:133,856,072...133,876,573

G

folylpolyglutamate synthase

increases expression

Triiodothyronine results in increased expression of FPGS mRNA

NCBI chr 3:15,972,800...15,993,592
Ensembl chr 3:15,972,800...15,993,563

G

follicle stimulating hormone subunit beta

multiple interactions

FSHB protein promotes the reaction [Triiodothyronine results in increased expression of INHBB mRNA]; Triiodothyronine promotes the reaction [FSHB protein results in increased expression of INHBB mRNA]

NCBI chr 3:93,548,560...93,552,370
Ensembl chr 3:93,548,560...93,552,370

G

FXYD domain-containing ion transport regulator 2

increases expression

Triiodothyronine results in increased expression of FXYD2 mRNA

NCBI chr 8:45,712,901...45,720,032
Ensembl chr 8:45,712,903...45,720,203

G

glucose-6-phosphatase catalytic subunit 1

multiple interactions
increases expression

(4-(4-hydroxy-3-isopropyl-5-(4-nitrophenylethynyl)benzyl)-3,5-dimethylphenoxy)acetic acid inhibits the reaction [Triiodothyronine results in increased expression of G6PC1 mRNA]; SJ 000311413 inhibits the reaction [Triiodothyronine results in increased expression of G6PC1 mRNA]

NCBI chr10:86,307,400...86,318,766
Ensembl chr10:86,257,668...86,333,804

G

growth associated protein 43

increases expression

Triiodothyronine results in increased expression of GAP43 mRNA; Triiodothyronine results in increased expression of GAP43 protein

NCBI chr11:58,376,371...58,470,047
Ensembl chr11:58,376,371...58,470,045

G

glucosylceramidase beta 1

increases activity

Triiodothyronine results in increased activity of GBA1 protein

NCBI chr 2:174,609,437...174,615,457
Ensembl chr 2:174,609,403...174,618,263

G

GTP cyclohydrolase 1

increases expression

Triiodothyronine results in increased expression of GCH1 mRNA

NCBI chr15:20,404,267...20,437,727
Ensembl chr15:20,402,527...20,437,698

G

growth hormone 1

multiple interactions
increases expression

Alitretinoin promotes the reaction [Triiodothyronine results in increased expression of GH1 mRNA]; Amiodarone inhibits the reaction [Triiodothyronine results in increased expression of GH1 mRNA]; bisphenol A promotes the reaction [Triiodothyronine results in increased expression of and results in increased secretion of GH protein]; Butyric Acid inhibits the reaction [Triiodothyronine results in increased expression of GH1 mRNA]; Dexamethasone promotes the reaction [Triiodothyronine results in increased expression of GH1 mRNA]; Edetic Acid promotes the reaction [Triiodothyronine results in increased expression of GH1 mRNA]; P4HB protein inhibits the reaction [Triiodothyronine results in increased expression of and results in increased secretion of GH protein]; P4HB protein inhibits the reaction [Triiodothyronine results in increased expression of GH mRNA]; P4HB protein inhibits the reaction [Triiodothyronine results in increased expression of GH1 mRNA]; P4HB protein inhibits the reaction [Triiodothyronine results in increased expression of GH1 protein]; Pentetic Acid promotes the reaction [Alitretinoin promotes the reaction [Triiodothyronine results in increased expression of GH1 mRNA]]; Pentetic Acid promotes the reaction [Tretinoin promotes the reaction [Triiodothyronine results in increased expression of GH1 mRNA]]; Pentetic Acid promotes the reaction [Triiodothyronine promotes the reaction [Alitretinoin results in increased expression of GH1 mRNA]]; Pentetic Acid promotes the reaction [Triiodothyronine promotes the reaction [Tretinoin results in increased expression of GH1 mRNA]]; Pentetic Acid promotes the reaction [Triiodothyronine results in increased expression of GH1 mRNA]; Polybrominated Biphenyls analog inhibits the reaction [Triiodothyronine results in increased expression of GH1 mRNA]; Polybrominated Biphenyls analog inhibits the reaction [Triiodothyronine results in increased expression of GH1 protein]; Tretinoin promotes the reaction [Triiodothyronine results in increased expression of GH1 mRNA]; Triiodothyronine promotes the reaction [Alitretinoin results in increased expression of GH1 mRNA]; Triiodothyronine promotes the reaction [Tretinoin results in increased expression of GH1 mRNA]; Triiodothyronine results in increased expression of and results in increased secretion of GH protein; Zinc inhibits the reaction [Pentetic Acid promotes the reaction [Alitretinoin promotes the reaction [Triiodothyronine results in increased expression of GH1 mRNA]]]; Zinc inhibits the reaction [Pentetic Acid promotes the reaction [Tretinoin promotes the reaction [Triiodothyronine results in increased expression of GH1 mRNA]]]; Zinc inhibits the reaction [Pentetic Acid promotes the reaction [Triiodothyronine promotes the reaction [Alitretinoin results in increased expression of GH1 mRNA]]]; Zinc inhibits the reaction [Pentetic Acid promotes the reaction [Triiodothyronine promotes the reaction [Tretinoin results in increased expression of GH1 mRNA]]]; Zinc inhibits the reaction [Pentetic Acid promotes the reaction [Triiodothyronine results in increased expression of GH1 mRNA]]
Triiodothyronine results in increased expression of GH mRNA; Triiodothyronine results in increased expression of GH1 mRNA; Triiodothyronine results in increased expression of GH1 protein

PMID:2211641 PMID:2910914 PMID:10720163 PMID:15240998 PMID:17090972 More...

NCBI chr10:91,228,102...91,230,079
Ensembl chr10:91,228,103...91,230,078

G

growth hormone releasing hormone

multiple interactions

Triiodothyronine promotes the reaction [Dexamethasone results in increased expression of GHRH mRNA]

NCBI chr 3:145,992,762...146,012,528
Ensembl chr 3:145,992,763...146,011,889

G

gap junction protein, alpha 1

increases expression
multiple interactions

Triiodothyronine results in increased expression of GJA1 protein
[Triiodothyronine co-treated with Chlorpyrifos] results in increased expression of GJA1 mRNA; [Triiodothyronine co-treated with Ethylenethiourea] results in increased expression of GJA1 mRNA
Triiodothyronine results in increased expression of GJA1 mRNA

PMID:15685554 PMID:34571837

NCBI chr20:35,756,007...35,768,481
Ensembl chr20:35,755,991...35,768,582

G

glycerophosphocholine phosphodiesterase 1

increases expression

Triiodothyronine results in increased expression of GPCPD1 mRNA

NCBI chr 3:119,787,681...119,832,550
Ensembl chr 3:119,787,682...119,832,517

G

glycerol-3-phosphate dehydrogenase 2

increases expression

Triiodothyronine results in increased expression of GPD2 mRNA

NCBI chr 3:41,800,552...41,937,729
Ensembl chr 3:41,801,930...41,936,901

G

glutamic--pyruvic transaminase

multiple interactions

Triiodothyronine inhibits the reaction [BMS201038 results in increased expression of GPT protein]

NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494

G

glutathione peroxidase 3

multiple interactions

Triiodothyronine inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in decreased expression of GPX3 protein]

NCBI chr10:39,028,624...39,036,695
Ensembl chr10:39,028,570...39,037,035

G

glutamate ionotropic receptor kainate type subunit 4

increases expression

Triiodothyronine results in increased expression of GRIK4 mRNA

NCBI chr 8:42,903,043...43,331,990
Ensembl chr 8:42,905,056...43,193,751

G

glycogen synthase kinase 3 beta

multiple interactions

Triiodothyronine inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in decreased phosphorylation of GSK3B protein]

NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646

G

glutathione S-transferase alpha 2

multiple interactions

Triiodothyronine inhibits the reaction [goitrin results in increased expression of GSTA2 protein]

NCBI chr 8:79,184,535...79,196,827
Ensembl chr 8:79,184,322...79,196,798

G

glutathione S-transferase pi 1

multiple interactions

Triiodothyronine inhibits the reaction [goitrin results in increased expression of GSTP1 protein]

NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226

G

glutathione S-transferase pi 3

decreases expression

Triiodothyronine results in decreased expression of GSTP3 mRNA

NCBI chr 1:201,355,682...201,358,216
Ensembl chr 1:201,355,682...201,358,330

G

GULP PTB domain containing engulfment adaptor 1

decreases expression

Triiodothyronine results in decreased expression of GULP1 mRNA

NCBI chr 9:46,622,699...46,899,005
Ensembl chr 9:46,622,669...46,899,005

G

H1.5 linker histone, cluster member

increases expression

Triiodothyronine results in increased expression of H1-5 mRNA

NCBI chr17:42,726,132...42,727,162
Ensembl chr17:42,726,127...42,769,160

G

H2A.X variant histone

increases phosphorylation
multiple interactions

Triiodothyronine analog results in increased phosphorylation of H2AX protein
Triiodothyronine analog promotes the reaction [Cisplatin results in increased expression of H2AX protein]

NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239

G

hemoglobin alpha, adult chain 1

increases expression

Triiodothyronine results in increased expression of HBA-A1 mRNA

NCBI chr10:15,337,265...15,338,121
Ensembl chr10:15,307,815...15,338,392

G

hemoglobin subunit beta

increases expression

Triiodothyronine results in increased expression of HBB mRNA

NCBI chr 1:158,250,421...158,251,832
Ensembl chr 1:158,120,200...158,252,012

G

hemoglobin subunit gamma 1

increases expression

Triiodothyronine results in increased expression of HBG1 mRNA

NCBI chr 1:158,271,871...158,273,426
Ensembl chr 1:158,271,873...158,273,425

G

hyperpolarization activated cyclic nucleotide gated potassium and sodium channel 2

increases expression

Triiodothyronine results in increased expression of HCN2 mRNA

NCBI chr 7:9,969,801...9,988,839
Ensembl chr 7:9,970,368...9,988,841

G

histidine decarboxylase

decreases expression

Triiodothyronine results in decreased expression of HDC mRNA

NCBI chr 3:113,847,256...113,865,334
Ensembl chr 3:113,847,260...113,865,341

G

heart development protein with EGF-like domains 1

increases expression

Triiodothyronine results in increased expression of HEG1 mRNA

NCBI chr11:67,006,954...67,095,020
Ensembl chr11:66,957,190...67,095,051

G

hepatocyte growth factor

multiple interactions

[BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of HGF mRNA

NCBI chr 4:18,673,736...18,745,582
Ensembl chr 4:18,677,101...18,745,409

G

hypoxia inducible factor 1 subunit alpha

increases expression

Triiodothyronine results in increased expression of HIF1A mRNA

NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261

G

HIG1 hypoxia inducible domain family, member 1A

increases expression

Triiodothyronine results in increased expression of HIGD1A mRNA

NCBI chr 8:121,514,152...121,523,382
Ensembl chr 8:121,514,156...121,523,443

G

histone cell cycle regulator

increases expression

Triiodothyronine results in increased expression of HIRA mRNA

NCBI chr11:82,024,469...82,133,212
Ensembl chr11:82,024,469...82,133,529

G

3-hydroxy-3-methylglutaryl-CoA synthase 1

increases expression

Triiodothyronine results in increased expression of HMGCS1 mRNA

NCBI chr 2:51,649,368...51,667,100
Ensembl chr 2:51,649,497...51,667,100

G

3-hydroxy-3-methylglutaryl-CoA synthase 2

increases expression

Triiodothyronine results in increased expression of HMGCS2 mRNA

NCBI chr 2:185,875,609...185,903,505
Ensembl chr 2:185,875,616...185,902,130

G

heme oxygenase 1

multiple interactions

Triiodothyronine inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in decreased expression of HMOX1 protein]

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

heterogeneous nuclear ribonucleoprotein H3

increases expression

Triiodothyronine results in increased expression of HNRNPH3 mRNA

NCBI chr20:25,616,400...25,625,814
Ensembl chr20:25,614,733...25,625,750

G

HR, lysine demethylase and nuclear receptor corepressor

increases expression

Triiodothyronine results in increased expression of HR mRNA

PMID:25172293 PMID:26096596

NCBI chr15:45,626,835...45,646,313
Ensembl chr15:45,626,835...45,646,313

G

HscB mitochondrial iron-sulfur cluster co-chaperone

decreases expression

Triiodothyronine results in decreased expression of HSCB mRNA

NCBI chr12:45,821,527...45,831,902
Ensembl chr12:45,821,555...45,831,909

G

hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1

multiple interactions

2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [Triiodothyronine inhibits the reaction [[NR4A1 co-treated with THRA] results in increased expression of HSD3B1 mRNA]]; 2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [Triiodothyronine promotes the reaction [[NR4A1 co-treated with THRA] results in increased expression of HSD3B1 mRNA]]; Triiodothyronine inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HSD3B1 mRNA]; Triiodothyronine inhibits the reaction [[NR4A1 co-treated with THRA] results in increased expression of HSD3B1 mRNA]; Triiodothyronine promotes the reaction [[NR4A1 co-treated with THRA] results in increased expression of HSD3B1 mRNA]

NCBI chr 2:186,169,864...186,175,984
Ensembl chr 2:186,169,863...186,175,999

G

hormonally upregulated Neu-associated kinase

increases expression

Triiodothyronine results in increased expression of HUNK mRNA

NCBI chr11:29,641,122...29,758,392
Ensembl chr11:29,640,775...29,757,526

G

isocitrate dehydrogenase (NADP(+)) 1

increases expression

Triiodothyronine results in increased expression of IDH1 mRNA

NCBI chr 9:66,534,146...66,563,703
Ensembl chr 9:66,534,146...66,563,708

G

insulin-like growth factor 1

multiple interactions
increases expression
increases secretion

Estradiol inhibits the reaction [Triiodothyronine results in increased expression of IGF1 mRNA]; Estradiol inhibits the reaction [Triiodothyronine results in increased secretion of IGF1 protein]

NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296

G

insulin-like growth factor binding protein 2

increases expression

Triiodothyronine results in increased expression of IGFBP2 mRNA

NCBI chr 9:74,415,574...74,442,945
Ensembl chr 9:74,415,546...74,442,937

G

IgLON family member 5

increases expression

Triiodothyronine results in increased expression of IGLON5 mRNA

NCBI chr 1:93,880,906...93,898,929
Ensembl chr 1:93,881,991...93,898,754

G

interleukin 10

multiple interactions

[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL10 mRNA; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL10 mRNA]

NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313

G

interleukin 17A

multiple interactions

[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL17A mRNA; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL17A mRNA]

NCBI chr 9:23,144,402...23,147,889
Ensembl chr 9:23,144,402...23,147,889

G

interleukin 1 alpha

increases expression

Triiodothyronine results in increased expression of IL1A mRNA

NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822

G

interleukin 1 beta

multiple interactions
increases expression

[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of IL1B mRNA; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of IL1B mRNA]; THRA protein affects the reaction [Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased expression of IL1B mRNA]]; THRA protein affects the reaction [Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased secretion of IL1B protein]]; Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased expression of IL1B mRNA]; Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased secretion of IL1B protein]
Triiodothyronine inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of IL1B protein]; Triiodothyronine inhibits the reaction [Propylthiouracil results in increased expression of IL1B protein]
Triiodothyronine results in increased expression of IL1B mRNA

PMID:29796989 PMID:32223187 PMID:32816093 PMID:33476690 PMID:36868496

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 24

increases expression

Triiodothyronine results in increased expression of IL24 mRNA

NCBI chr13:42,353,089...42,358,487
Ensembl chr13:42,353,090...42,358,487

G

interleukin 6

multiple interactions

THRA protein affects the reaction [Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased expression of IL6 mRNA]]; THRA protein affects the reaction [Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased secretion of IL6 protein]]; Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased expression of IL6 mRNA]; Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased secretion of IL6 protein]
Triiodothyronine inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of IL6 protein]; Triiodothyronine inhibits the reaction [Propylthiouracil results in increased expression of IL6 mRNA]

PMID:29796989 PMID:32223187 PMID:36868496

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

inhibin subunit alpha

multiple interactions

[Triiodothyronine co-treated with Ethylenethiourea] results in decreased expression of INHA mRNA

NCBI chr 9:76,994,465...76,997,366
Ensembl chr 9:76,993,589...76,997,248

G

inhibin subunit beta B

multiple interactions
increases expression

FSHB protein promotes the reaction [Triiodothyronine results in increased expression of INHBB mRNA]; Triiodothyronine promotes the reaction [FSHB protein results in increased expression of INHBB mRNA]

NCBI chr13:30,530,860...30,536,566
Ensembl chr13:30,530,860...30,537,832

G

insulin 1

multiple interactions

(+)-JQ1 compound inhibits the reaction [[Triiodothyronine co-treated with Rosiglitazone co-treated with INS1 protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of UCP1 mRNA]; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of CS mRNA; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of HGF mRNA; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of MMP2 mRNA; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of PPARGC1A mRNA; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of PPARGC1A protein; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of PRDM16 mRNA; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of UCP1 mRNA; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of UCP1 protein; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of VEGFA mRNA; [Triiodothyronine co-treated with Rosiglitazone co-treated with INS1 protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of UCP1 mRNA

PMID:26972250 PMID:33091441

NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536

G

insulin 2

multiple interactions

[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein co-treated with Indomethacin co-treated with Rosiglitazone co-treated with Triiodothyronine] results in increased expression of KCNMA1 mRNA; [Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein co-treated with Indomethacin co-treated with Rosiglitazone co-treated with Triiodothyronine] results in increased expression of KCNMA1 protein; [Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein co-treated with Indomethacin co-treated with Rosiglitazone co-treated with Triiodothyronine] results in increased expression of SLC2A4 mRNA; [Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein co-treated with Indomethacin co-treated with Rosiglitazone co-treated with Triiodothyronine] results in increased expression of SLC2A4 protein
[Orlistat co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of NFE2L2 mRNA; [Orlistat co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of TGFB1 mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL10 mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL17A mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FABP4 mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of IL1B mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARA mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARG mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARG protein; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARGC1A mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of SREBF1 mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA; [Rosmarinic Acid co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of NFE2L2 mRNA; [Rosmarinic Acid co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of TGFB1 mRNA; [Rosmarinic Acid co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of NFKBIA mRNA; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA]; Orlistat promotes the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein]; Rosmarinic Acid affects the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA mRNA]; Rosmarinic Acid affects the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARGC1A mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL10 mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL17A mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FABP4 mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of IL1B mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARA mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARG protein]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of SREBF1 mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA]

PMID:27605626 PMID:33476690

NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775

G

insulin induced gene 1

increases expression

Triiodothyronine results in increased expression of INSIG1 mRNA

NCBI chr 4:7,315,494...7,323,972
Ensembl chr 4:7,315,495...7,323,952

G

interferon regulatory factor 1

multiple interactions

[Triiodothyronine co-treated with Tetrachlorodibenzodioxin] results in increased expression of IRF1 mRNA

NCBI chr10:37,917,155...37,924,166
Ensembl chr10:37,916,670...37,924,166

G

integrin subunit alpha M

multiple interactions

Triiodothyronine promotes the reaction [tamibarotene results in increased expression of ITGAM protein]

NCBI chr 1:182,659,047...182,709,501
Ensembl chr 1:182,659,000...182,709,503

G

integrin subunit beta 3

multiple interactions

ITGB3 inhibits the reaction [bisphenol A inhibits the reaction [Triiodothyronine inhibits the reaction [NCOR1 protein binds to and results in decreased activity of THRB protein]]]; ITGB3 inhibits the reaction [bisphenol A inhibits the reaction [Triiodothyronine inhibits the reaction [NCOR2 protein binds to and results in decreased activity of THRB protein]]]

NCBI chr10:89,509,917...89,564,679
Ensembl chr10:89,509,989...89,564,679

G

integrin subunit beta 5

increases expression
decreases expression

Triiodothyronine results in increased expression of ITGB5 mRNA
Triiodothyronine results in decreased expression of ITGB5 mRNA

NCBI chr11:66,828,428...66,944,231
Ensembl chr11:66,829,285...66,944,472

G

inositol-tetrakisphosphate 1-kinase

increases expression

Triiodothyronine results in increased expression of ITPK1 mRNA

NCBI chr 6:121,710,750...121,844,501
Ensembl chr 6:121,710,755...121,844,107

G

inositol 1,4,5-trisphosphate receptor, type 1

increases expression

Triiodothyronine results in increased expression of ITPR1 mRNA

NCBI chr 4:141,187,377...141,554,240
Ensembl chr 4:141,187,418...141,510,491

G

KANTR integral membrane protein

increases expression

Triiodothyronine results in increased expression of KANTR mRNA

NCBI chr X:21,402,717...21,430,663

G

potassium voltage-gated channel subfamily A member 1

increases expression

Triiodothyronine results in increased expression of KCNA1 mRNA

NCBI chr 4:159,464,223...159,472,905
Ensembl chr 4:159,464,188...159,472,682

G

potassium voltage-gated channel subfamily A member 4

decreases expression

Triiodothyronine results in decreased expression of KCNA4 mRNA

NCBI chr 3:93,756,399...93,778,004
Ensembl chr 3:93,756,446...93,769,162

G

potassium calcium-activated channel subfamily M alpha 1

multiple interactions

[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein co-treated with Indomethacin co-treated with rosiglitazone co-treated with Triiodothyronine] results in increased expression of KCNMA1 mRNA; [Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein co-treated with Indomethacin co-treated with rosiglitazone co-treated with Triiodothyronine] results in increased expression of KCNMA1 protein

NCBI chr15:302,480...1,007,675
Ensembl chr15:302,214...1,001,198

G

potassium channel tetramerization domain containing 12

decreases expression

Triiodothyronine results in decreased expression of KCTD12 mRNA

NCBI chr15:79,800,078...79,806,017
Ensembl chr15:79,801,191...79,806,282

G

kinesin family member 1B

increases expression

Triiodothyronine results in increased expression of KIF1B mRNA

NCBI chr 5:159,607,697...159,742,778
Ensembl chr 5:159,561,271...159,742,778

G

KLF transcription factor 9

decreases expression
increases expression

Triiodothyronine results in decreased expression of KLF9 mRNA
Triiodothyronine results in increased expression of KLF9 mRNA

PMID:15507505 PMID:23397585 PMID:26096596 PMID:35172007

NCBI chr 1:220,700,108...220,725,110
Ensembl chr 1:220,700,108...220,725,037

G

keratin 13

multiple interactions

[Triiodothyronine co-treated with Tetrachlorodibenzodioxin] results in decreased expression of KRT13 mRNA

NCBI chr10:85,051,887...85,056,099
Ensembl chr10:85,051,889...85,056,084

G

kynurenine aminotransferase 1

decreases activity

Triiodothyronine results in decreased activity of KYAT1 protein

NCBI chr 3:13,459,598...13,493,308
Ensembl chr 3:13,459,591...13,493,355

G

low density lipoprotein receptor

multiple interactions
increases expression

Amiodarone promotes the reaction [Triiodothyronine results in increased expression of LDLR mRNA]; desethylamiodarone promotes the reaction [Triiodothyronine results in increased expression of LDLR mRNA]
Triiodothyronine inhibits the reaction [Amiodarone results in decreased expression of LDLR protein]

PMID:9071962 PMID:9712728

NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580

G

leucine-rich repeat LGI family, member 4

increases expression

Triiodothyronine results in increased expression of LGI4 mRNA

NCBI chr 1:86,294,539...86,305,909
Ensembl chr 1:86,295,074...86,304,874

G

LIM homeobox 3

decreases expression

Triiodothyronine results in decreased expression of LHX3 mRNA

NCBI chr 3:9,026,432...9,035,122
Ensembl chr 3:9,027,425...9,034,480

G

lipase E, hormone sensitive type

increases expression

Triiodothyronine results in increased expression of LIPE mRNA

NCBI chr 1:80,965,612...80,984,313
Ensembl chr 1:80,965,627...80,984,310

G

LIM and cysteine-rich domains 1

decreases expression

Triiodothyronine results in decreased expression of LMCD1 mRNA

NCBI chr 4:145,393,153...145,452,049
Ensembl chr 4:145,393,145...145,452,046

G

lipin 3

increases expression

Triiodothyronine results in increased expression of LPIN3 mRNA

NCBI chr 3:149,533,719...149,558,494
Ensembl chr 3:149,534,051...149,558,327

G

lipoprotein lipase

increases expression

Triiodothyronine results in increased expression of LPL mRNA

NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249

G

LDL receptor related protein 1

multiple interactions

Triiodothyronine inhibits the reaction [[Iodine deficiency co-treated with Propylthiouracil] results in decreased expression of LRP1 protein]

NCBI chr 7:63,380,325...63,461,029
Ensembl chr 7:63,380,356...63,460,910

G

lanosterol synthase

increases expression

Triiodothyronine results in increased expression of LSS mRNA

NCBI chr20:12,091,138...12,118,858
Ensembl chr20:12,092,774...12,118,762

G

leukotriene B4 receptor

multiple interactions

[Triiodothyronine co-treated with Tetrachlorodibenzodioxin] results in decreased expression of LTB4R mRNA

NCBI chr15:29,263,199...29,265,716

G

LYR motif containing 9

decreases expression

Triiodothyronine results in decreased expression of LYRM9 mRNA

NCBI chr10:63,725,718...63,739,772
Ensembl chr10:63,725,743...63,739,772

G

microtubule-associated protein 1 light chain 3 beta

increases lipidation
increases expression
multiple interactions

Triiodothyronine results in increased lipidation of MAP1LC3B protein
Triiodothyronine results in increased expression of MAP1LC3B mRNA
bafilomycin A1 promotes the reaction [Triiodothyronine results in increased lipidation of MAP1LC3B protein]; Triiodothyronine promotes the reaction [bafilomycin A1 results in increased lipidation of MAP1LC3B protein]

NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690

G

mitogen activated protein kinase 1

multiple interactions
increases expression

Triiodothyronine inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; Triiodothyronine promotes the reaction [FGF18 protein results in increased phosphorylation of MAPK1 protein]; Triiodothyronine promotes the reaction [FGF2 protein results in increased phosphorylation of MAPK1 protein]; Triiodothyronine promotes the reaction [FGF9 protein results in increased phosphorylation of MAPK1 protein]; U 0126 inhibits the reaction [Triiodothyronine results in increased expression of MAPK1 mRNA]
Triiodothyronine promotes the reaction [FGF2 protein results in increased phosphorylation of and results in increased activity of MAPK1 protein]

PMID:12805413 PMID:16150908 PMID:28315333

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

multiple interactions
increases expression

Triiodothyronine inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]; Triiodothyronine promotes the reaction [FGF18 protein results in increased phosphorylation of MAPK3 protein]; Triiodothyronine promotes the reaction [FGF2 protein results in increased phosphorylation of MAPK3 protein]; Triiodothyronine promotes the reaction [FGF9 protein results in increased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [Triiodothyronine results in increased expression of MAPK3 mRNA]
Triiodothyronine promotes the reaction [FGF2 protein results in increased phosphorylation of and results in increased activity of MAPK3 protein]

PMID:12805413 PMID:16150908 PMID:28315333

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

microtubule-associated protein tau

multiple interactions

Triiodothyronine inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of and results in increased phosphorylation of MAPT protein]

NCBI chr10:89,138,644...89,236,137
Ensembl chr10:89,138,627...89,236,129

G

myoglobin

affects expression

Triiodothyronine affects the expression of MB mRNA

NCBI chr 7:108,759,903...108,767,134
Ensembl chr 7:108,759,904...108,767,383

G

myelin basic protein

increases expression

Triiodothyronine results in increased expression of MBP protein alternative form

NCBI chr18:75,855,878...75,966,404
Ensembl chr18:75,855,878...75,966,404

G

malic enzyme 1

increases expression

Triiodothyronine results in increased expression of ME1 mRNA

PMID:15953391 PMID:29357290

NCBI chr 8:87,549,043...87,660,251
Ensembl chr 8:87,549,043...87,660,304

G

meiosis specific with coiled-coil domain

decreases expression

Triiodothyronine results in decreased expression of MEIOC mRNA

NCBI chr10:87,628,807...87,646,485
Ensembl chr10:87,628,875...87,646,752

G

MFSD2 lysolipid transporter A, lysophospholipid

increases expression

Triiodothyronine results in increased expression of MFSD2A mRNA

NCBI chr 5:135,225,801...135,240,744
Ensembl chr 5:135,225,816...135,240,690

G

MIER family member 3

decreases expression

Triiodothyronine results in decreased expression of MIER3 mRNA

NCBI chr 2:43,287,546...43,316,422
Ensembl chr 2:43,287,916...43,316,136

G

multiple inositol-polyphosphate phosphatase 1, pseudogene 1

increases expression

Triiodothyronine results in increased expression of MINPP1-PS1 mRNA

NCBI chr 1:74,017,248...74,019,633
Ensembl chr 1:230,354,438...230,379,730

G

marker of proliferation Ki-67

increases expression
multiple interactions

Triiodothyronine results in increased expression of MKI67 mRNA
U 0126 inhibits the reaction [Triiodothyronine results in increased expression of MKI67 mRNA]

NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762

G

monocyte to macrophage differentiation-associated 2

increases expression

Triiodothyronine results in increased expression of MMD2 mRNA

NCBI chr12:11,962,733...12,009,776
Ensembl chr12:11,962,757...12,009,773

G

matrix metallopeptidase 11

multiple interactions
increases expression

(4-(4-hydroxy-3-isopropyl-5-(4-nitrophenylethynyl)benzyl)-3,5-dimethylphenoxy)acetic acid inhibits the reaction [Triiodothyronine results in increased expression of MMP11 mRNA]; SJ 000311413 inhibits the reaction [Triiodothyronine results in increased expression of MMP11 mRNA]

NCBI chr20:12,730,846...12,739,629
Ensembl chr20:12,730,836...12,739,628

G

matrix metallopeptidase 2

multiple interactions

Triiodothyronine inhibits the reaction [TGFB1 protein results in increased secretion of MMP2 protein]
[BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of MMP2 mRNA

PMID:18031379 PMID:33091441

NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870

G

myeloperoxidase

multiple interactions

[Triiodothyronine co-treated with Hexachlorocyclohexane] results in increased activity of MPO protein

NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819

G

musashi RNA-binding protein 1

multiple interactions

[pyriproxyfen metabolite co-treated with Triiodothyronine] results in increased expression of MSI1 mRNA

NCBI chr12:41,158,301...41,251,134
Ensembl chr12:41,158,599...41,191,076

G

mechanistic target of rapamycin kinase

decreases phosphorylation

Triiodothyronine results in decreased phosphorylation of MTOR protein

NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311

G

myosin heavy chain 6

multiple interactions
increases expression

S100A6 protein inhibits the reaction [Triiodothyronine results in increased expression of MYH6 mRNA]; Triiodothyronine inhibits the reaction [Phenylephrine results in decreased expression of MYH6 mRNA]

PMID:11577024 PMID:15578571 PMID:15652358

NCBI chr15:28,418,120...28,442,316
Ensembl chr15:28,417,616...28,441,720

G

myosin heavy chain 7

multiple interactions
decreases expression

Triiodothyronine inhibits the reaction [Phenylephrine results in increased expression of MYH7 mRNA]
Triiodothyronine results in decreased expression of MYH7 mRNA

PMID:11577024 PMID:15578571

NCBI chr15:28,446,550...28,469,888
Ensembl chr15:28,446,550...28,468,217

G

Na+ dependent glucose transporter 1

increases expression

Triiodothyronine results in increased expression of NAGLT1 mRNA

NCBI chr20:43,411,550...43,423,873
Ensembl chr20:43,394,843...43,423,873

G

non-SMC condensin II complex, subunit G2

decreases expression

Triiodothyronine results in decreased expression of NCAPG2 mRNA

NCBI chr 6:137,342,449...137,418,083
Ensembl chr 6:137,342,943...137,415,159

G

nuclear receptor coactivator 1

multiple interactions

[Triiodothyronine co-treated with NCOA1 protein] results in increased activity of THRB protein; bisphenol A inhibits the reaction [[Triiodothyronine co-treated with NCOA1 protein] results in increased activity of THRB protein]

NCBI chr 6:27,232,609...27,507,992
Ensembl chr 6:27,232,611...27,475,664

G

nuclear receptor coactivator 2

multiple interactions

Triiodothyronine promotes the reaction [NCOA2 protein binds to THRA protein]; Triiodothyronine promotes the reaction [NCOA2 protein binds to THRB protein]; Triiodothyronine promotes the reaction [THRA protein binds to NCOA2 protein]; Triiodothyronine promotes the reaction [THRB protein binds to NCOA2 protein]

PMID:29146198 PMID:31566444

NCBI chr 5:5,835,642...6,069,693
Ensembl chr 5:5,835,706...6,067,451

G

nuclear receptor co-repressor 1

multiple interactions

2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Triiodothyronine inhibits the reaction [THRB protein binds to NCOR1 protein]]; AG 1879 inhibits the reaction [Triiodothyronine inhibits the reaction [THRB protein binds to NCOR1 protein]]; bisphenol A inhibits the reaction [Triiodothyronine inhibits the reaction [NCOR1 protein binds to and results in decreased activity of THRB protein]]; bisphenol A inhibits the reaction [Triiodothyronine inhibits the reaction [THRB protein binds to NCOR1 protein]]; ITGB3 inhibits the reaction [bisphenol A inhibits the reaction [Triiodothyronine inhibits the reaction [NCOR1 protein binds to and results in decreased activity of THRB protein]]]; SRC inhibits the reaction [bisphenol A inhibits the reaction [Triiodothyronine inhibits the reaction [NCOR1 protein binds to and results in decreased activity of THRB protein]]]; tetraiodothyroacetic acid inhibits the reaction [Triiodothyronine inhibits the reaction [THRB protein binds to NCOR1 protein]]; Triiodothyronine inhibits the reaction [NCOR1 protein binds to and results in decreased activity of THRB protein]; Triiodothyronine inhibits the reaction [THRB protein binds to NCOR1 protein]

NCBI chr10:46,999,536...47,142,294
Ensembl chr10:46,999,536...47,141,032

G

nuclear receptor co-repressor 2

multiple interactions

2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Triiodothyronine inhibits the reaction [THRB protein binds to NCOR2 protein]]; AG 1879 inhibits the reaction [Triiodothyronine inhibits the reaction [THRB protein binds to NCOR2 protein]]; bisphenol A inhibits the reaction [Triiodothyronine inhibits the reaction [THRB protein binds to NCOR2 protein]]; ITGB3 inhibits the reaction [bisphenol A inhibits the reaction [Triiodothyronine inhibits the reaction [NCOR2 protein binds to and results in decreased activity of THRB protein]]]; SRC inhibits the reaction [bisphenol A inhibits the reaction [Triiodothyronine inhibits the reaction [NCOR2 protein binds to and results in decreased activity of THRB protein]]]; tetraiodothyroacetic acid inhibits the reaction [Triiodothyronine inhibits the reaction [THRB protein binds to NCOR2 protein]]; Triiodothyronine inhibits the reaction [THRB protein binds to NCOR2 protein]

NCBI chr12:31,466,418...31,628,319
Ensembl chr12:31,466,412...31,628,319

G

NADH:ubiquinone oxidoreductase subunit A5

increases expression

Triiodothyronine results in increased expression of NDUFA5 mRNA

NCBI chr 4:52,997,327...53,005,685
Ensembl chr 4:52,995,546...53,005,598

G

neurofilament light chain

decreases expression

Triiodothyronine results in decreased expression of NEFL mRNA

NCBI chr15:42,301,920...42,305,793
Ensembl chr15:42,301,916...42,305,793

G

neurofilament medium chain

decreases expression

Triiodothyronine results in decreased expression of NEFM mRNA

NCBI chr15:42,360,449...42,365,753
Ensembl chr15:42,360,454...42,365,755

G

NFE2 like bZIP transcription factor 2

multiple interactions

[Orlistat co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of NFE2L2 mRNA; [Rosmarinic Acid co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of NFE2L2 mRNA
Triiodothyronine inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in decreased expression of NFE2L2 protein]

PMID:33476690 PMID:36868496

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

nuclear factor kappa B subunit 1

increases activity
multiple interactions

Triiodothyronine results in increased activity of NFKB1 protein
Hexachlorocyclohexane affects the reaction [Triiodothyronine results in increased activity of NFKB1 protein]

NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404

G

NFKB inhibitor alpha

multiple interactions

[Rosmarinic Acid co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of NFKBIA mRNA

NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941

G

neuronatin

decreases expression

Triiodothyronine results in decreased expression of NNAT mRNA

NCBI chr 3:146,225,941...146,228,868
Ensembl chr 3:146,226,407...146,228,834

G

nephronectin

increases expression

Triiodothyronine results in increased expression of NPNT mRNA

NCBI chr 2:221,391,151...221,459,527
Ensembl chr 2:221,391,153...221,459,401

G

nuclear receptor subfamily 0, group B, member 2

increases expression

Triiodothyronine results in increased expression of NR0B2 mRNA

NCBI chr 5:145,779,294...145,782,609
Ensembl chr 5:145,779,294...145,782,609

G

nuclear receptor subfamily 1, group I, member 2

multiple interactions

Triiodothyronine binds to and results in increased activity of NR1I2 protein

NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658

G

nuclear receptor subfamily 4, group A, member 1

multiple interactions

2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [Triiodothyronine inhibits the reaction [[NR4A1 co-treated with THRA] results in increased expression of HSD3B1 mRNA]]; 2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [Triiodothyronine inhibits the reaction [[NR4A1 co-treated with THRA] results in increased expression of STAR mRNA]]; 2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [Triiodothyronine promotes the reaction [[NR4A1 co-treated with THRA] results in increased expression of HSD3B1 mRNA]]; Triiodothyronine inhibits the reaction [[NR4A1 co-treated with THRA] results in increased expression of HSD3B1 mRNA]; Triiodothyronine inhibits the reaction [[NR4A1 co-treated with THRA] results in increased expression of STAR mRNA]; Triiodothyronine promotes the reaction [[NR4A1 co-treated with THRA] results in increased expression of HSD3B1 mRNA]

NCBI chr 7:132,368,399...132,389,300
Ensembl chr 7:132,374,840...132,389,297

G

neurogranin

increases expression
multiple interactions

Triiodothyronine results in increased expression of NRGN mRNA; Triiodothyronine results in increased expression of NRGN protein
Triiodothyronine inhibits the reaction [Propylthiouracil results in decreased expression of and results in decreased phosphorylation of NRGN protein]; Triiodothyronine inhibits the reaction [Propylthiouracil results in decreased expression of NRGN mRNA]

PMID:15708448 PMID:29796989

NCBI chr 8:37,255,462...37,263,659
Ensembl chr 8:37,256,930...37,257,516

G

neuropilin 1

increases expression

Triiodothyronine results in increased expression of NRP1 mRNA

NCBI chr19:56,359,455...56,514,628
Ensembl chr19:56,359,455...56,513,633

G

NAD(P) dependent steroid dehydrogenase-like

increases expression

Triiodothyronine results in increased expression of NSDHL mRNA

NCBI chr X:150,775,034...150,807,161
Ensembl chr X:150,775,080...150,807,142

G

NMDA receptor synaptonuclear signaling and neuronal migration factor

increases expression

Triiodothyronine results in increased expression of NSMF mRNA

NCBI chr 3:7,861,846...7,870,615
Ensembl chr 3:7,861,872...7,870,614

G

5' nucleotidase, ecto

increases expression
increases activity

Triiodothyronine results in increased expression of NT5E mRNA
Triiodothyronine results in increased activity of NT5E protein

NCBI chr 8:89,271,046...89,314,918
Ensembl chr 8:89,270,696...89,314,881

G

nudix hydrolase 7

increases expression

Triiodothyronine results in increased expression of NUDT7 mRNA

NCBI chr19:42,125,679...42,151,198
Ensembl chr19:42,125,711...42,151,081

G

nucleoporin 214

multiple interactions

[Triiodothyronine co-treated with Tetrachlorodibenzodioxin] results in decreased expression of NUP214 mRNA

NCBI chr 3:15,255,111...15,340,568
Ensembl chr 3:15,255,119...15,340,568

G

occludin

increases expression

Triiodothyronine results in increased expression of OCLN mRNA

NCBI chr 2:31,657,217...31,707,466
Ensembl chr 2:31,657,220...31,764,150

G

oligodendrocyte transcription factor 2

decreases expression

Triiodothyronine results in decreased expression of OLIG2 protein

NCBI chr11:30,475,510...30,478,886
Ensembl chr11:30,475,398...30,480,152

G

olfactory receptor 59

increases expression

Triiodothyronine results in increased expression of OLR59 mRNA

NCBI chr 1:157,193,051...157,227,707
Ensembl chr 1:157,193,080...157,211,179

G

oxidative stress induced growth inhibitor 1

increases expression

Triiodothyronine results in increased expression of OSGIN1 mRNA

NCBI chr19:47,471,750...47,500,517
Ensembl chr19:47,492,171...47,500,516

G

prolyl 4-hydroxylase subunit beta

multiple interactions
affects binding

4-OH-2',3,3',4',5'-pentachlorobiphenyl inhibits the reaction [Triiodothyronine binds to P4HB protein]; bisphenol A inhibits the reaction [Triiodothyronine binds to P4HB protein]; P4HB protein inhibits the reaction [Triiodothyronine results in increased expression of and results in increased secretion of GH protein]; P4HB protein inhibits the reaction [Triiodothyronine results in increased expression of GH mRNA]; P4HB protein inhibits the reaction [Triiodothyronine results in increased expression of GH1 mRNA]; P4HB protein inhibits the reaction [Triiodothyronine results in increased expression of GH1 protein]; Polychlorinated Biphenyls metabolite inhibits the reaction [Triiodothyronine binds to P4HB protein]

PMID:17928132 PMID:18515855 PMID:19374345 PMID:22201216

NCBI chr10:105,836,972...105,848,583
Ensembl chr10:105,836,982...105,848,500

G

peptidyl arginine deiminase 4

increases expression

Triiodothyronine results in increased expression of PADI4 mRNA

NCBI chr 5:153,041,351...153,074,412
Ensembl chr 5:153,041,352...153,074,362

G

poly (ADP-ribose) polymerase family, member 4

decreases expression

Triiodothyronine results in decreased expression of PARP4 mRNA

NCBI chr15:30,690,503...30,792,868
Ensembl chr15:30,686,613...30,828,810

G

phosphoenolpyruvate carboxykinase 1

multiple interactions
increases expression

SIRT1 protein affects the reaction [Triiodothyronine results in increased expression of PCK1 mRNA]
(4-(4-hydroxy-3-isopropyl-5-(4-nitrophenylethynyl)benzyl)-3,5-dimethylphenoxy)acetic acid inhibits the reaction [Triiodothyronine results in increased expression of PCK1 mRNA]; SJ 000311413 inhibits the reaction [Triiodothyronine results in increased expression of PCK1 mRNA]

PMID:21815645 PMID:23209300 PMID:30209975

NCBI chr 3:161,930,256...161,936,205
Ensembl chr 3:161,930,256...161,936,191

G

proliferating cell nuclear antigen

affects binding
increases expression
multiple interactions

Triiodothyronine analog binds to PCNA protein; Triiodothyronine binds to PCNA protein
Triiodothyronine results in increased expression of PCNA protein
THRB protein promotes the reaction [Triiodothyronine results in increased expression of PCNA protein]
Triiodothyronine analog inhibits the reaction [CDKN1A protein binds to PCNA protein]; Triiodothyronine analog inhibits the reaction [POLD3 protein binds to PCNA protein]; Triiodothyronine inhibits the reaction [CDKN1A protein binds to PCNA protein]

PMID:20638743 PMID:22383522

NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995

G

proprotein convertase subtilisin/kexin type 1

decreases expression

Triiodothyronine results in decreased expression of PCSK1 mRNA

NCBI chr 2:4,395,543...4,442,434
Ensembl chr 2:4,395,543...4,442,434

G

proprotein convertase subtilisin/kexin type 2

decreases expression

Triiodothyronine results in decreased expression of PCSK2 mRNA

NCBI chr 3:130,880,422...131,183,127
Ensembl chr 3:130,880,422...131,183,127

G

platelet derived growth factor receptor alpha

decreases expression

Triiodothyronine results in decreased expression of PDGFRA protein

NCBI chr14:33,005,838...33,054,347
Ensembl chr14:33,005,839...33,054,335

G

pyruvate dehydrogenase kinase 4

multiple interactions
increases expression

resveratrol promotes the reaction [Triiodothyronine results in increased expression of PDK4 mRNA]
resveratrol promotes the reaction [Triiodothyronine results in increased expression of PDK4 mRNA]; SIRT1 protein affects the reaction [Triiodothyronine results in increased expression of PDK4 mRNA]

NCBI chr 4:33,591,796...33,601,798
Ensembl chr 4:33,589,799...33,601,850

G

pyruvate dehydrogenase phosphatase catalytic subunit 2

increases expression

Triiodothyronine results in increased expression of PDP2 mRNA

NCBI chr19:386,408...394,068
Ensembl chr19:386,406...394,074

G

paternally expressed 10

increases expression

Triiodothyronine results in increased expression of PEG10 mRNA

NCBI chr 4:32,842,441...32,855,639
Ensembl chr 4:32,848,493...32,852,621

G

peroxisomal biogenesis factor 5

increases expression

Triiodothyronine results in increased expression of PEX5 mRNA

NCBI chr 4:157,270,671...157,296,432
Ensembl chr 4:157,270,672...157,296,431

G

phosphofructokinase, platelet

increases expression

Triiodothyronine results in increased expression of PFKP mRNA

NCBI chr17:63,729,743...63,794,026
Ensembl chr17:63,729,780...63,794,018

G

phosphoethanolamine/phosphocholine phosphatase 1

increases expression

Triiodothyronine results in increased expression of PHOSPHO1 mRNA

NCBI chr10:80,762,062...80,769,596
Ensembl chr10:80,760,792...80,770,342

G

phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit delta

increases expression

Triiodothyronine results in increased expression of PIK3CD mRNA

NCBI chr 5:160,094,952...160,142,962
Ensembl chr 5:160,094,952...160,120,930

G

phospholipase A2 group VI

increases expression

Triiodothyronine results in increased expression of PLA2G6 mRNA

NCBI chr 7:110,851,378...110,891,557
Ensembl chr 7:110,851,378...110,891,114

G

phospholipase D family, member 5

increases expression

Triiodothyronine results in increased expression of PLD5 mRNA

NCBI chr13:87,895,694...88,232,868
Ensembl chr13:87,896,369...88,232,868

G

perilipin 2

increases expression

Triiodothyronine results in increased expression of PLIN2 mRNA

NCBI chr 5:101,156,648...101,211,738
Ensembl chr 5:101,154,411...101,242,319

G

perilipin 3

multiple interactions

[THRA protein co-treated with Triiodothyronine] promotes the reaction [ANGPTL8 protein binds to PLIN3 protein]

NCBI chr 9:1,111,178...1,123,057
Ensembl chr 9:1,102,366...1,123,147

G

plexin C1

increases expression

Triiodothyronine results in increased expression of PLXNC1 mRNA

NCBI chr 7:29,390,038...29,543,985
Ensembl chr 7:29,390,048...29,543,779

G

peripheral myelin protein 22

increases expression

Triiodothyronine results in increased expression of PMP22 mRNA

NCBI chr10:47,795,709...47,825,715
Ensembl chr10:47,795,709...47,825,714

G

patatin-like phospholipase domain containing 2

increases expression
decreases phosphorylation

Triiodothyronine results in increased expression of PNPLA2 mRNA
Triiodothyronine results in decreased phosphorylation of PNPLA2 protein

NCBI chr 1:196,552,723...196,557,805
Ensembl chr 1:196,552,723...196,557,805

G

podocalyxin-like

increases expression

Triiodothyronine results in increased expression of PODXL mRNA

NCBI chr 4:60,135,124...60,181,829
Ensembl chr 4:60,135,109...60,181,899

G

DNA polymerase delta 3, accessory subunit

multiple interactions

Triiodothyronine analog inhibits the reaction [POLD3 protein binds to PCNA protein]

NCBI chr 1:154,417,893...154,456,687
Ensembl chr 1:154,418,084...154,456,665

G

DNA polymerase gamma, catalytic subunit

multiple interactions

[Triiodothyronine co-treated with Tetrachlorodibenzodioxin] results in decreased expression of POLG mRNA

NCBI chr 1:133,382,764...133,399,578
Ensembl chr 1:133,382,766...133,398,567

G

protein-O-mannosyltransferase 1

increases expression

Triiodothyronine results in increased expression of POMT1 mRNA

NCBI chr 3:15,520,717...15,538,579
Ensembl chr 3:15,520,481...15,538,581

G

POU class 5 homeobox 1

increases expression
multiple interactions

Triiodothyronine results in increased expression of POU5F1 mRNA
Chlorpyrifos inhibits the reaction [Triiodothyronine results in increased expression of POU5F1 mRNA]; Ethylenethiourea inhibits the reaction [Triiodothyronine results in increased expression of POU5F1 mRNA]

NCBI chr20:3,223,128...3,227,891
Ensembl chr20:3,223,129...3,227,891

G

peroxisome proliferator activated receptor alpha

multiple interactions

[GW 7647 results in increased activity of PPARA protein] promotes the reaction [Phenobarbital results in increased degradation of Triiodothyronine]; [pirinixic acid results in increased activity of PPARA protein] promotes the reaction [Phenobarbital results in increased degradation of Triiodothyronine]; [Triiodothyronine co-treated with Oleic Acid co-treated with Palmitic Acid] results in decreased expression of PPARA mRNA
[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARA mRNA; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARA mRNA]; Triiodothyronine inhibits the reaction [Acetaminophen results in decreased expression of PPARA mRNA]

PMID:19631232 PMID:25048947 PMID:33476690 PMID:35662663

NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346

G

peroxisome proliferator-activated receptor delta

multiple interactions

[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA]

NCBI chr20:6,298,785...6,363,970
Ensembl chr20:6,298,785...6,363,968

G

peroxisome proliferator-activated receptor gamma

multiple interactions

Triiodothyronine inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of PPARG mRNA]
[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARG mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARG protein; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARG protein]; Triiodothyronine binds to and results in increased activity of PPARG protein

PMID:25048947 PMID:33049310 PMID:33476690

NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468

G

PPARG coactivator 1 alpha

increases expression
multiple interactions

Triiodothyronine results in increased expression of PPARGC1A mRNA
[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARGC1A mRNA; Rosmarinic Acid affects the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARGC1A mRNA]
[BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of PPARGC1A mRNA; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of PPARGC1A protein

PMID:23209300 PMID:30209975 PMID:33091441 PMID:33476690

NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656

G

PR/SET domain 16

increases expression
multiple interactions

Triiodothyronine results in increased expression of PRDM16 mRNA
[BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of PRDM16 mRNA

PMID:30209975 PMID:33091441

NCBI chr 5:164,879,864...165,203,986
Ensembl chr 5:164,880,587...165,203,601

G

proline and arginine rich end leucine rich repeat protein

decreases expression

Triiodothyronine results in decreased expression of PRELP mRNA

NCBI chr13:45,368,407...45,391,480
Ensembl chr13:45,370,533...45,380,270

G

prickle planar cell polarity protein 2

decreases expression

Triiodothyronine results in decreased expression of PRICKLE2 mRNA

NCBI chr 4:124,869,655...125,214,862
Ensembl chr 4:124,869,552...125,214,824

G

prolactin

decreases expression
increases secretion
multiple interactions

Triiodothyronine results in decreased expression of PRL mRNA; Triiodothyronine results in decreased expression of PRL protein
Triiodothyronine results in increased secretion of PRL protein
bisphenol A inhibits the reaction [Triiodothyronine results in increased secretion of PRL protein]; Chlorodiphenyl (54% Chlorine) promotes the reaction [Triiodothyronine results in increased secretion of PRL protein]

PMID:3734668 PMID:17615682

NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062

G

prokineticin receptor 1

increases expression

Triiodothyronine results in increased expression of PROKR1 mRNA

NCBI chr 4:120,022,301...120,033,367
Ensembl chr 4:120,021,747...120,033,379

G

prostate stem cell antigen

multiple interactions
increases expression

4-OH-2',3,3',4',5'-pentachlorobiphenyl inhibits the reaction [Triiodothyronine results in increased expression of PSCA mRNA]; Polychlorinated Biphenyls inhibits the reaction [Triiodothyronine results in increased expression of PSCA mRNA]; Tetrachlorodibenzodioxin promotes the reaction [Triiodothyronine results in increased expression of PSCA mRNA]; Tetrachlorodibenzodioxin promotes the reaction [Triiodothyronine results in increased expression of PSCA protein]
Triiodothyronine results in increased expression of PSCA mRNA; Triiodothyronine results in increased expression of PSCA protein

NCBI chr 7:106,598,203...106,603,114
Ensembl chr 7:106,595,284...106,609,746

G

prostaglandin-endoperoxide synthase 2

increases expression

Triiodothyronine results in increased expression of PTGS2 mRNA

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

RAB23, member RAS oncogene family

decreases expression

Triiodothyronine results in decreased expression of RAB23 mRNA

NCBI chr 9:35,943,522...35,967,367
Ensembl chr 9:35,944,085...35,966,927

G

RAB3B, member RAS oncogene family

increases expression

Triiodothyronine results in increased expression of RAB3B mRNA

NCBI chr 5:123,629,562...123,697,410
Ensembl chr 5:123,644,423...123,697,401

G

RAP1A, member of RAS oncogene family

multiple interactions

RAP1A protein promotes the reaction [mono-(2-ethylhexyl)phthalate results in decreased expression of Triiodothyronine]

NCBI chr 2:193,208,631...193,286,513
Ensembl chr 2:193,208,635...193,286,501

G

retinoic acid receptor, beta

increases expression

Triiodothyronine results in increased expression of RARB mRNA

NCBI chr15:8,700,533...9,051,288
Ensembl chr15:8,406,492...9,051,288

G

RELA proto-oncogene, NF-kB subunit

multiple interactions
increases activity

Hexachlorocyclohexane affects the reaction [Triiodothyronine results in increased activity of RELA protein]

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

retinol saturase

increases expression

Triiodothyronine results in increased expression of RETSAT mRNA

NCBI chr 4:104,653,306...104,662,069
Ensembl chr 4:104,653,155...104,668,310

G

ras homolog family member V

increases expression

Triiodothyronine results in increased expression of RHOV mRNA

NCBI chr 3:106,260,774...106,270,009
Ensembl chr 3:106,260,776...106,269,479

G

replication protein A2

increases phosphorylation

Triiodothyronine analog results in increased phosphorylation of RPA2 protein

NCBI chr 5:144,976,789...144,989,445
Ensembl chr 5:144,976,748...144,987,350

G

ribosomal protein S6 kinase B1

multiple interactions
decreases phosphorylation

6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [Triiodothyronine results in decreased phosphorylation of RPS6KB1 protein]

NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908

G

retinoid X receptor beta

increases expression

Triiodothyronine results in increased expression of RXRB mRNA

NCBI chr20:4,816,813...4,823,267
Ensembl chr20:4,816,815...4,828,773

G

retinoid X receptor gamma

increases expression

Triiodothyronine results in increased expression of RXRG mRNA

NCBI chr13:79,743,430...79,785,173
Ensembl chr13:79,743,563...79,785,167

G

S100 calcium binding protein A6

multiple interactions

S100A6 protein inhibits the reaction [Triiodothyronine results in increased expression of MYH6 mRNA]

NCBI chr 2:176,100,619...176,102,181
Ensembl chr 2:176,100,899...176,102,180

G

sterol-C5-desaturase

increases expression

Triiodothyronine results in increased expression of SC5D mRNA

NCBI chr 8:42,629,649...42,641,257
Ensembl chr 8:42,632,672...42,641,273

G

stearoyl-CoA desaturase

increases expression

Triiodothyronine results in increased expression of SCD1 mRNA

NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562

G

serpin family A member 6

increases expression

Triiodothyronine results in increased expression of SERPINA6 mRNA

NCBI chr 6:122,780,040...122,790,274
Ensembl chr 6:122,780,043...122,790,349

G

serpin family A member 7

affects binding

Triiodothyronine binds to SERPINA7 protein

PMID:20804816 PMID:21517007

NCBI chr X:102,663,242...102,722,319
Ensembl chr X:102,663,405...102,669,040

G

sigma non-opioid intracellular receptor 1

increases expression

Triiodothyronine results in increased expression of SIGMAR1 mRNA

NCBI chr 5:56,904,155...56,907,012
Ensembl chr 5:56,904,159...56,907,017

G

sirtuin 1

multiple interactions
increases expression
affects response to substance

SIRT1 protein affects the reaction [Triiodothyronine results in decreased activity of SREBF1 protein]; SIRT1 protein affects the reaction [Triiodothyronine results in decreased expression of SREBF1 mRNA]; SIRT1 protein affects the reaction [Triiodothyronine results in increased expression of CPT1A mRNA]; SIRT1 protein affects the reaction [Triiodothyronine results in increased expression of CPT1A protein]; SIRT1 protein affects the reaction [Triiodothyronine results in increased expression of PCK1 mRNA]; SIRT1 protein affects the reaction [Triiodothyronine results in increased expression of PDK4 mRNA]
Triiodothyronine results in increased expression of SIRT1 mRNA
SIRT1 protein affects the susceptibility to Triiodothyronine

NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260

G

solute carrier family 10 member 2

increases expression

Triiodothyronine results in increased expression of SLC10A2 mRNA

NCBI chr16:84,386,528...84,409,475
Ensembl chr16:84,374,862...84,409,475

G

solute carrier family 15 member 1

multiple interactions
decreases expression

resveratrol inhibits the reaction [Triiodothyronine results in decreased expression of SLC15A1 mRNA]; resveratrol inhibits the reaction [Triiodothyronine results in decreased expression of SLC15A1 protein]
Triiodothyronine results in decreased expression of SLC15A1 mRNA; Triiodothyronine results in decreased expression of SLC15A1 protein

NCBI chr15:98,537,641...98,582,544
Ensembl chr15:98,537,641...98,582,545

G

solute carrier family 16 member 2

multiple interactions
increases uptake

bisphenol A inhibits the reaction [SLC16A2 protein results in increased uptake of Triiodothyronine]; bosutinib inhibits the reaction [SLC16A2 protein results in increased uptake of Triiodothyronine]; Dasatinib inhibits the reaction [SLC16A2 protein results in increased uptake of Triiodothyronine]; Desipramine inhibits the reaction [SLC16A2 protein results in increased uptake of Triiodothyronine]; Genistein inhibits the reaction [SLC16A2 protein results in increased uptake of Triiodothyronine]; Imatinib Mesylate inhibits the reaction [SLC16A2 protein results in increased uptake of Triiodothyronine]; Indocyanine Green inhibits the reaction [SLC16A2 protein results in increased uptake of Triiodothyronine]; Meclofenamic Acid inhibits the reaction [SLC16A2 protein results in increased uptake of Triiodothyronine]; Phloretin inhibits the reaction [SLC16A2 protein results in increased uptake of Triiodothyronine]; Sulfobromophthalein inhibits the reaction [SLC16A2 protein results in increased uptake of Triiodothyronine]

NCBI chr X:68,725,365...68,848,572
Ensembl chr X:68,723,261...68,848,771

G

solute carrier family 16 member 3

increases expression

Triiodothyronine results in increased expression of SLC16A3 mRNA

NCBI chr10:106,212,679...106,222,564
Ensembl chr10:106,212,778...106,222,562

G

solute carrier family 16, member 6

increases expression
multiple interactions

Triiodothyronine results in increased expression of SLC16A6 mRNA
(4-(4-hydroxy-3-isopropyl-5-(4-nitrophenylethynyl)benzyl)-3,5-dimethylphenoxy)acetic acid inhibits the reaction [Triiodothyronine results in increased expression of SLC16A6 mRNA]

NCBI chr10:94,424,377...94,447,482
Ensembl chr10:94,426,244...94,448,779

G

solute carrier family 1 member 2

increases expression

Triiodothyronine results in increased expression of SLC1A2 mRNA

NCBI chr 3:89,005,129...89,135,469
Ensembl chr 3:89,005,129...89,126,498

G

solute carrier family 25 member 25

increases expression

Triiodothyronine results in increased expression of SLC25A25 mRNA

NCBI chr 3:15,708,702...15,742,195
Ensembl chr 3:15,708,703...15,742,216

G

solute carrier family 2 member 1

increases expression

Triiodothyronine results in increased expression of SLC2A1 mRNA

NCBI chr 5:132,717,196...132,745,416
Ensembl chr 5:132,717,196...132,745,416

G

solute carrier family 2 member 4

multiple interactions

[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein co-treated with Indomethacin co-treated with rosiglitazone co-treated with Triiodothyronine] results in increased expression of SLC2A4 mRNA; [Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein co-treated with Indomethacin co-treated with rosiglitazone co-treated with Triiodothyronine] results in increased expression of SLC2A4 protein

NCBI chr10:54,666,015...54,671,581
Ensembl chr10:54,666,015...54,671,565

G

solute carrier family 2 member 5

multiple interactions

[Triiodothyronine co-treated with Fructose] results in increased expression of SLC2A5 mRNA

NCBI chr 5:160,583,055...160,609,994
Ensembl chr 5:160,583,234...160,611,106

G

solute carrier family 38, member 2

increases expression

Triiodothyronine results in increased expression of SLC38A2 mRNA

NCBI chr 7:127,851,267...127,863,482
Ensembl chr 7:127,851,267...127,863,436

G

solute carrier family 43 member 2

increases expression

Triiodothyronine results in increased expression of SLC43A2 mRNA

NCBI chr10:60,375,462...60,420,838
Ensembl chr10:60,376,559...60,418,244

G

SLC51 subunit beta

increases expression
multiple interactions

Triiodothyronine results in increased expression of SLC51B mRNA
(4-(4-hydroxy-3-isopropyl-5-(4-nitrophenylethynyl)benzyl)-3,5-dimethylphenoxy)acetic acid inhibits the reaction [Triiodothyronine results in increased expression of SLC51B mRNA]

NCBI chr 8:65,931,891...65,939,953
Ensembl chr 8:65,931,890...65,940,145

G

solute carrier family 7 member 11

increases expression

Triiodothyronine results in increased expression of SLC7A11 mRNA

NCBI chr 2:134,382,002...134,517,622
Ensembl chr 2:133,963,107...134,517,536

G

secretory leukocyte peptidase inhibitor

increases expression

Triiodothyronine results in increased expression of SLPI mRNA

NCBI chr 3:153,082,208...153,084,457
Ensembl chr 3:153,082,369...153,084,453

G

sushi, nidogen and EGF-like domains 1

increases expression

Triiodothyronine results in increased expression of SNED1 mRNA

NCBI chr 9:93,774,087...93,834,003
Ensembl chr 9:93,774,119...93,830,694

G

small nucleolar RNA, H/ACA box 28

decreases expression

Triiodothyronine results in decreased expression of SNORA28 mRNA

NCBI chr 6:130,591,965...130,592,090
Ensembl chr 6:130,591,965...130,592,090

G

superoxide dismutase 1

multiple interactions
decreases expression

Triiodothyronine inhibits the reaction [Paraquat results in decreased expression of SOD1 mRNA]; Triiodothyronine inhibits the reaction [THRA protein results in increased expression of SOD1 mRNA]; Triiodothyronine inhibits the reaction [THRB protein results in increased expression of SOD1 mRNA]
Triiodothyronine results in decreased expression of SOD1 mRNA

NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249

G

SRY-box transcription factor 10

multiple interactions

[pyriproxyfen metabolite co-treated with Triiodothyronine] results in decreased expression of SOX10 mRNA

NCBI chr 7:110,725,274...110,734,651
Ensembl chr 7:110,725,274...110,735,544

G

SRY-box transcription factor 9

multiple interactions
decreases expression

[Triiodothyronine co-treated with Ethylenethiourea] results in decreased expression of SOX9 mRNA
Triiodothyronine results in decreased expression of SOX9 mRNA

NCBI chr10:97,806,485...97,811,994
Ensembl chr10:97,806,485...97,811,994

G

spen family transcriptional repressor

increases expression

Triiodothyronine results in increased expression of SPEN mRNA

NCBI chr 5:153,775,287...153,848,677
Ensembl chr 5:153,776,234...153,848,811

G

serine palmitoyltransferase, long chain base subunit 2

increases expression

Triiodothyronine results in increased expression of SPTLC2 mRNA

NCBI chr 6:106,948,682...107,031,532
Ensembl chr 6:106,950,949...107,031,542

G

sequestosome 1

multiple interactions
increases expression

[THRA protein co-treated with Triiodothyronine] results in decreased expression of SQSTM1 protein; Ammonium Chloride inhibits the reaction [[THRA protein co-treated with Triiodothyronine] results in decreased expression of SQSTM1 protein]; ANGPTL8 protein affects the reaction [[THRA protein co-treated with Triiodothyronine] results in decreased expression of SQSTM1 protein]; Chloroquine inhibits the reaction [[THRA protein co-treated with Triiodothyronine] results in decreased expression of SQSTM1 protein]
Triiodothyronine results in increased expression of SQSTM1 mRNA

PMID:24262987 PMID:30209975

NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673

G

SRC proto-oncogene, non-receptor tyrosine kinase

multiple interactions

SRC inhibits the reaction [bisphenol A inhibits the reaction [Triiodothyronine inhibits the reaction [NCOR1 protein binds to and results in decreased activity of THRB protein]]]; SRC inhibits the reaction [bisphenol A inhibits the reaction [Triiodothyronine inhibits the reaction [NCOR2 protein binds to and results in decreased activity of THRB protein]]]

NCBI chr 3:146,091,969...146,139,492
Ensembl chr 3:146,091,841...146,139,476

G

sterol regulatory element binding transcription factor 1

multiple interactions
decreases expression
decreases activity

SIRT1 protein affects the reaction [Triiodothyronine results in decreased activity of SREBF1 protein]; SIRT1 protein affects the reaction [Triiodothyronine results in decreased expression of SREBF1 mRNA]
[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of SREBF1 mRNA; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of SREBF1 mRNA]

PMID:23209300 PMID:33476690

NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650

G

serine and arginine rich splicing factor 3

decreases expression

Triiodothyronine results in decreased expression of SFRS3 mRNA

NCBI chr20:7,091,928...7,101,860
Ensembl chr20:7,091,910...7,101,078

G

steroidogenic acute regulatory protein

multiple interactions

2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [Triiodothyronine inhibits the reaction [[NR4A1 co-treated with THRA] results in increased expression of STAR mRNA]]; [Triiodothyronine co-treated with Ethylenethiourea] results in decreased expression of STAR mRNA; Triiodothyronine inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR mRNA]; Triiodothyronine inhibits the reaction [[NR4A1 co-treated with THRA] results in increased expression of STAR mRNA]

PMID:21726595 PMID:34571837

NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672

G

StAR-related lipid transfer domain containing 8

increases expression

Triiodothyronine results in increased expression of STARD8 mRNA

NCBI chr X:64,079,079...64,196,052
Ensembl chr X:64,124,574...64,196,052

G

signal transducer and activator of transcription 1

multiple interactions

Triiodothyronine inhibits the reaction [FGF2 protein results in increased phosphorylation of STAT1 protein]

NCBI chr 9:49,419,561...49,459,969
Ensembl chr 9:49,419,340...49,588,540

G

signal transducer and activator of transcription 5A

increases expression

Triiodothyronine results in increased expression of STAT5A mRNA

NCBI chr10:85,785,537...85,809,869
Ensembl chr10:85,785,537...85,809,866

G

signal transducer and activator of transcription 5B

increases expression

Triiodothyronine results in increased expression of STAT5B mRNA

NCBI chr10:85,704,841...85,775,856
Ensembl chr10:85,705,670...85,775,668

G

serine/threonine kinase 19

increases expression

Triiodothyronine results in increased expression of STK19 mRNA

NCBI chr20:3,995,590...4,005,117
Ensembl chr20:3,995,587...4,005,116

G

stimulated by retinoic acid 8

decreases expression
multiple interactions

Triiodothyronine results in decreased expression of STRA8 mRNA
[Chlorpyrifos co-treated with Triiodothyronine] results in decreased expression of STRA8 mRNA; [Ethylenethiourea co-treated with Triiodothyronine] results in decreased expression of STRA8 mRNA

NCBI chr 4:63,601,443...63,624,777
Ensembl chr 4:63,601,604...63,624,771

G

sulfotransferase family 1A member 1

increases sulfation
multiple interactions
affects sulfation

SULT1A1 protein results in increased sulfation of Triiodothyronine
Triiodothyronine inhibits the reaction [SULT1A1 protein results in increased sulfation of 4-nitrophenol]
SULT1A1 gene polymorphism affects the sulfation of Triiodothyronine

PMID:11739018 PMID:15531517

NCBI chr 1:181,272,022...181,276,750
Ensembl chr 1:181,272,023...181,275,562

G

sulfotransferase family 2A member 1

increases expression

Triiodothyronine results in increased expression of SULT2A1 mRNA

NCBI chr 1:75,451,178...75,508,113
Ensembl chr 1:74,911,100...75,508,134

G

sulfotransferase family 4A, member 1

increases metabolic processing

SULT4A1 protein results in increased metabolism of Triiodothyronine

NCBI chr 7:115,216,066...115,240,156
Ensembl chr 7:115,216,066...115,240,085

G

synaptonemal complex protein 1

decreases expression
multiple interactions

Triiodothyronine results in decreased expression of SYCP1 mRNA
[Chlorpyrifos co-treated with Triiodothyronine] results in decreased expression of SYCP1 mRNA; [Ethylenethiourea co-treated with Triiodothyronine] results in decreased expression of SYCP1 mRNA

NCBI chr 2:190,296,688...190,456,687
Ensembl chr 2:190,296,954...190,456,737

G

TATA-box binding protein associated factor 5 like 1

increases expression

Triiodothyronine results in increased expression of TAF5L mRNA

NCBI chr19:51,991,704...52,011,001
Ensembl chr19:51,991,708...52,011,295

G

transcriptional and immune response regulator

multiple interactions
increases expression

SJ 000311413 inhibits the reaction [Triiodothyronine results in increased expression of TCIM mRNA]

NCBI chr16:67,595,762...67,597,055
Ensembl chr16:67,593,410...67,597,581

G

testis expressed 264

increases expression

Triiodothyronine results in increased expression of TEX264 mRNA

NCBI chr 8:107,295,806...107,322,858
Ensembl chr 8:107,295,806...107,323,232

G

transferrin

multiple interactions

[Orlistat co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of NFE2L2 mRNA; [Orlistat co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of TGFB1 mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL10 mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL17A mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FABP4 mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of IL1B mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARA mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARG mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARG protein; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARGC1A mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of SREBF1 mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA; [Rosmarinic Acid co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of NFE2L2 mRNA; [Rosmarinic Acid co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of TGFB1 mRNA; [Rosmarinic Acid co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of NFKBIA mRNA; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA]; Orlistat promotes the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein]; Rosmarinic Acid affects the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA mRNA]; Rosmarinic Acid affects the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARGC1A mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL10 mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL17A mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FABP4 mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of IL1B mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARA mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARG protein]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of SREBF1 mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA]

NCBI chr 8:103,789,780...103,816,487
Ensembl chr 8:103,767,995...103,816,511

G

transcription factor EB

increases expression

Triiodothyronine results in increased expression of TFEB mRNA

NCBI chr 9:13,198,890...13,254,726
Ensembl chr 9:13,198,891...13,254,714

G

transforming growth factor, beta 1

multiple interactions

Triiodothyronine inhibits the reaction [TGFB1 protein results in increased secretion of MMP2 protein]; Triiodothyronine promotes the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA]
[Orlistat co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of TGFB1 mRNA; [Rosmarinic Acid co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of TGFB1 mRNA

PMID:18031379 PMID:33476690

NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847

G

trans-golgi network protein 2

decreases expression
increases expression

Triiodothyronine results in decreased expression of TGOLN2 mRNA
Triiodothyronine results in increased expression of TGOLN2 mRNA

NCBI chr 4:104,663,356...104,671,208
Ensembl chr 4:104,663,353...104,671,164

G

thyroid hormone receptor alpha

multiple interactions
affects binding
increases expression
increases activity
decreases expression

(4-(4-hydroxy-3-isopropyl-5-(4-nitrophenylethynyl)benzyl)-3,5-dimethylphenoxy)acetic acid inhibits the reaction [Triiodothyronine results in increased expression of THRA mRNA]; 2,2',4,4'-tetrabromodiphenyl ether analog affects the reaction [Triiodothyronine binds to THRA protein]; 4,4'-bisphenol F inhibits the reaction [Triiodothyronine binds to THRA protein]; [THRA protein co-treated with Triiodothyronine] promotes the reaction [ANGPTL8 protein binds to PLIN3 protein]; [THRA protein co-treated with Triiodothyronine] results in decreased expression of SQSTM1 protein; [THRA protein co-treated with Triiodothyronine] results in increased expression of ANGPTL8 mRNA; [THRA protein co-treated with Triiodothyronine] results in increased expression of ANGPTL8 protein; Ammonium Chloride inhibits the reaction [[THRA protein co-treated with Triiodothyronine] results in decreased expression of SQSTM1 protein]; ANGPTL8 protein affects the reaction [[THRA protein co-treated with Triiodothyronine] results in decreased expression of SQSTM1 protein]; bisphenol A inhibits the reaction [Triiodothyronine binds to THRA protein]; bisphenol A inhibits the reaction [Triiodothyronine results in increased activity of THRA protein]; bisphenol S inhibits the reaction [Triiodothyronine binds to THRA protein]; Chloroquine inhibits the reaction [[THRA protein co-treated with Triiodothyronine] results in decreased expression of SQSTM1 protein]; daidzein promotes the reaction [Triiodothyronine results in increased activity of THRA protein]; Genistein promotes the reaction [Triiodothyronine results in increased activity of THRA protein]; KB 130015 inhibits the reaction [Triiodothyronine binds to and results in increased activity of THRA protein]; pentabromodiphenyl ether analog inhibits the reaction [Triiodothyronine binds to THRA protein]; Polybrominated Biphenyls metabolite inhibits the reaction [Triiodothyronine results in increased activity of THRA protein]; tetrabromobisphenol A inhibits the reaction [Triiodothyronine binds to THRA protein]; tetrabromobisphenol A inhibits the reaction [Triiodothyronine results in increased activity of THRA protein]; tetrachlorodian inhibits the reaction [Triiodothyronine results in increased activity of THRA protein]; THRA protein affects the reaction [Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased cleavage of CASP3 protein]]; THRA protein affects the reaction [Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased expression of CASP3 mRNA]]; THRA protein affects the reaction [Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased expression of CYCS mRNA]]; THRA protein affects the reaction [Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased expression of IL1B mRNA]]; THRA protein affects the reaction [Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased expression of IL6 mRNA]]; THRA protein affects the reaction [Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased expression of TNF mRNA]]; THRA protein affects the reaction [Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased secretion of IL1B protein]]; THRA protein affects the reaction [Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased secretion of IL6 protein]]; THRA protein affects the reaction [Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased secretion of TNF protein]]; tribromodiphenyl ether 28 analog affects the reaction [Triiodothyronine binds to THRA protein]; Triiodothyronine binds to and results in increased activity of THRA protein; Triiodothyronine inhibits the reaction [THRA protein results in increased expression of SOD1 mRNA]; Triiodothyronine promotes the reaction [NCOA2 protein binds to THRA protein]; Triiodothyronine promotes the reaction [THRA protein binds to NCOA2 protein]
2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [Triiodothyronine inhibits the reaction [[NR4A1 co-treated with THRA] results in increased expression of HSD3B1 mRNA]]; 2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [Triiodothyronine inhibits the reaction [[NR4A1 co-treated with THRA] results in increased expression of STAR mRNA]]; 2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [Triiodothyronine promotes the reaction [[NR4A1 co-treated with THRA] results in increased expression of HSD3B1 mRNA]]; 2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [Triiodothyronine results in increased expression of THRA mRNA]; [Triiodothyronine co-treated with Chlorpyrifos] results in decreased expression of THRA mRNA; [Triiodothyronine co-treated with Ethylenethiourea] results in decreased expression of THRA mRNA; CSK protein promotes the reaction [Tetrachlorodibenzodioxin promotes the reaction [Triiodothyronine binds to THRA protein]]; Tetrachlorodibenzodioxin promotes the reaction [Triiodothyronine binds to THRA protein]; Triiodothyronine inhibits the reaction [[NR4A1 co-treated with THRA] results in increased expression of HSD3B1 mRNA]; Triiodothyronine inhibits the reaction [[NR4A1 co-treated with THRA] results in increased expression of STAR mRNA]; Triiodothyronine promotes the reaction [[NR4A1 co-treated with THRA] results in increased expression of HSD3B1 mRNA]
[bisphenol A co-treated with Estradiol co-treated with Triiodothyronine] results in increased expression of THRA mRNA; [bisphenol A co-treated with Triiodothyronine] results in increased expression of THRA mRNA; Polybrominated Biphenyls inhibits the reaction [Triiodothyronine results in increased activity of THRA protein]; Polybrominated Biphenyls metabolite inhibits the reaction [Triiodothyronine binds to THRA protein]; THRA protein alternative form affects the reaction [Triiodothyronine promotes the reaction [Thiazolidinediones results in increased expression of UCP2]]; Triiodothyronine binds to and results in increased activity of THRA protein; Triiodothyronine inhibits the reaction [Propylthiouracil results in decreased expression of THRA mRNA]
Triiodothyronine results in decreased expression of THRA mRNA
Triiodothyronine results in increased expression of THRA mRNA; Triiodothyronine results in increased expression of THRA protein

PMID:7684602 PMID:9664232 PMID:11806713 PMID:12109914 PMID:12414890 More...

NCBI chr10:83,701,885...83,729,408
Ensembl chr10:83,700,755...83,729,936

G

thyroid hormone receptor beta

multiple interactions
increases expression
decreases expression
affects binding
increases response to substance
increases activity

(4-(4-hydroxy-3-isopropyl-5-(4-nitrophenylethynyl)benzyl)-3,5-dimethylphenoxy)acetic acid inhibits the reaction [Triiodothyronine results in increased expression of THRB mRNA]; 2,2',4,4'-tetrabromodiphenyl ether analog affects the reaction [Triiodothyronine binds to THRB protein]; 2,2',4,4'-tetrabromodiphenyl ether metabolite inhibits the reaction [Triiodothyronine binds to THRB protein]; 2,3,4,7,8-pentachlorodibenzofuran inhibits the reaction [Triiodothyronine results in increased expression of THRB mRNA]; 2,4,6-tribromophenol inhibits the reaction [Triiodothyronine binds to THRB protein]; 2,4,6-trichlorophenol inhibits the reaction [Triiodothyronine binds to THRB protein]; 2,4,6-triiodophenol inhibits the reaction [Triiodothyronine binds to THRB protein]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Triiodothyronine inhibits the reaction [THRB protein binds to NCOR1 protein]]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Triiodothyronine inhibits the reaction [THRB protein binds to NCOR2 protein]]; 4,4'-bisphenol F inhibits the reaction [Triiodothyronine binds to THRB protein]; 4,4'-hexafluorisopropylidene diphenol inhibits the reaction [Triiodothyronine binds to THRB protein]; 4-nonylphenol inhibits the reaction [Triiodothyronine results in increased activity of THRB protein]; 4-OH-2',3,3',4',5'-pentachlorobiphenyl inhibits the reaction [Triiodothyronine results in increased expression of THRB mRNA]; 6-OH-BDE-47 inhibits the reaction [Triiodothyronine binds to THRB protein]; [THRB protein co-treated with Triiodothyronine] results in increased expression of ANGPTL8 mRNA; [Triiodothyronine co-treated with NCOA1 protein] results in increased activity of THRB protein; AG 1879 inhibits the reaction [Triiodothyronine inhibits the reaction [THRB protein binds to NCOR1 protein]]; AG 1879 inhibits the reaction [Triiodothyronine inhibits the reaction [THRB protein binds to NCOR2 protein]]; Amiodarone inhibits the reaction [Triiodothyronine results in increased activity of THRB protein]; bisphenol A analog inhibits the reaction [Triiodothyronine binds to THRB protein]; bisphenol A inhibits the reaction [[Triiodothyronine co-treated with NCOA1 protein] results in increased activity of THRB protein]; bisphenol A inhibits the reaction [Triiodothyronine binds to THRB protein]; bisphenol A inhibits the reaction [Triiodothyronine inhibits the reaction [NCOR1 protein binds to and results in decreased activity of THRB protein]]; bisphenol A inhibits the reaction [Triiodothyronine inhibits the reaction [THRB protein binds to NCOR1 protein]]; bisphenol A inhibits the reaction [Triiodothyronine inhibits the reaction [THRB protein binds to NCOR2 protein]]; bisphenol A inhibits the reaction [Triiodothyronine results in increased activity of THRB protein]; bisphenol S analog inhibits the reaction [Triiodothyronine binds to THRB protein]; bisphenol S analog inhibits the reaction [Triiodothyronine results in increased activity of THRB protein]; bisphenol S inhibits the reaction [Triiodothyronine binds to THRB protein]; bisphenol S inhibits the reaction [Triiodothyronine results in increased activity of THRB protein]; cyhalothrin inhibits the reaction [Triiodothyronine results in increased activity of THRB protein]; daidzein promotes the reaction [Triiodothyronine results in increased activity of THRB protein]; deoxynivalenol inhibits the reaction [Triiodothyronine results in increased activity of THRB protein]; desethylamiodarone inhibits the reaction [Triiodothyronine binds to THRB protein alternative form]; Genistein promotes the reaction [Triiodothyronine results in increased activity of THRB protein]; ITGB3 inhibits the reaction [bisphenol A inhibits the reaction [Triiodothyronine inhibits the reaction [NCOR1 protein binds to and results in decreased activity of THRB protein]]]; ITGB3 inhibits the reaction [bisphenol A inhibits the reaction [Triiodothyronine inhibits the reaction [NCOR2 protein binds to and results in decreased activity of THRB protein]]]; KB 130015 inhibits the reaction [Triiodothyronine binds to and results in increased activity of THRB protein]; methoxyacetic acid promotes the reaction [Triiodothyronine results in increased activity of THRB protein]; pentabromodiphenyl ether analog inhibits the reaction [Triiodothyronine binds to THRB protein]; pentabromophenol inhibits the reaction [Triiodothyronine binds to THRB protein]; Polybrominated Biphenyls metabolite inhibits the reaction [Triiodothyronine results in increased activity of THRB protein]; SRC inhibits the reaction [bisphenol A inhibits the reaction [Triiodothyronine inhibits the reaction [NCOR1 protein binds to and results in decreased activity of THRB protein]]]; SRC inhibits the reaction [bisphenol A inhibits the reaction [Triiodothyronine inhibits the reaction [NCOR2 protein binds to and results in decreased activity of THRB protein]]]; systhane inhibits the reaction [Triiodothyronine results in increased activity of THRB protein]; T-2 Toxin inhibits the reaction [Triiodothyronine results in increased activity of THRB protein]; tetrabromobisphenol A inhibits the reaction [Triiodothyronine binds to THRB protein]; tetrabromobisphenol A inhibits the reaction [Triiodothyronine results in increased activity of THRB protein]; tetrachlorodian analog inhibits the reaction [Triiodothyronine binds to THRB protein]; tetrachlorodian inhibits the reaction [Triiodothyronine results in increased activity of THRB protein]; tetraiodothyroacetic acid inhibits the reaction [Triiodothyronine inhibits the reaction [THRB protein binds to NCOR1 protein]]; tetraiodothyroacetic acid inhibits the reaction [Triiodothyronine inhibits the reaction [THRB protein binds to NCOR2 protein]]; Thyroxine inhibits the reaction [Triiodothyronine binds to THRB protein]; Tretinoin inhibits the reaction [Triiodothyronine results in increased activity of THRB protein]; tribromodiphenyl ether 28 analog affects the reaction [Triiodothyronine binds to THRB protein]; Triclosan inhibits the reaction [Triiodothyronine binds to THRB protein]; Triiodothyronine binds to and results in increased activity of THRB protein; Triiodothyronine inhibits the reaction [NCOR1 protein binds to and results in decreased activity of THRB protein]; Triiodothyronine inhibits the reaction [THRB protein binds to NCOR1 protein]; Triiodothyronine inhibits the reaction [THRB protein binds to NCOR2 protein]; Triiodothyronine inhibits the reaction [THRB protein results in increased expression of SOD1 mRNA]; Triiodothyronine promotes the reaction [NCOA2 protein binds to THRB protein]; Triiodothyronine promotes the reaction [THRB protein binds to NCOA2 protein]; Zearalenone inhibits the reaction [Triiodothyronine results in increased activity of THRB protein]
Triiodothyronine results in decreased expression of THRB mRNA
THRB protein results in increased susceptibility to Triiodothyronine
Chlorpyrifos inhibits the reaction [Triiodothyronine results in increased expression of THRB mRNA]; Ethylenethiourea inhibits the reaction [Triiodothyronine results in increased expression of THRB mRNA]; THRB protein promotes the reaction [Triiodothyronine results in decreased expression of CDKN1B protein]; THRB protein promotes the reaction [Triiodothyronine results in increased expression of CCND1 protein]; THRB protein promotes the reaction [Triiodothyronine results in increased expression of PCNA protein]
Triiodothyronine results in increased expression of THRB mRNA; Triiodothyronine results in increased expression of THRB protein
[bisphenol A co-treated with Estradiol co-treated with Triiodothyronine] results in increased expression of THRB mRNA; [bisphenol A co-treated with Triiodothyronine] results in increased expression of THRB mRNA; Butyric Acid inhibits the reaction [Triiodothyronine results in increased expression of THRB mRNA]; desethylamiodarone inhibits the reaction [Triiodothyronine binds to THRB protein]; Polybrominated Biphenyls inhibits the reaction [Triiodothyronine results in increased activity of THRB protein]; THRB protein alternative form affects the reaction [Triiodothyronine promotes the reaction [Thiazolidinediones results in increased expression of UCP2]]; THRB protein promotes the reaction [Triiodothyronine results in increased expression of ATP2A2 mRNA]; Triiodothyronine inhibits the reaction [Phenylephrine results in decreased expression of THRB mRNA]; Triiodothyronine inhibits the reaction [Phenylephrine results in decreased expression of THRB protein]

PMID:2211641 PMID:8137729 PMID:11577024 PMID:11806713 PMID:12109914 More...

NCBI chr15:7,685,180...8,031,920
Ensembl chr15:7,685,180...7,882,916

G

thyroid hormone responsive

multiple interactions
increases expression

Triiodothyronine inhibits the reaction [Amiodarone results in increased expression of THRSP mRNA]
[Chlorpyrifos co-treated with Triiodothyronine] results in increased expression of THRSP mRNA; [Ethylenethiourea co-treated with Triiodothyronine] results in increased expression of THRSP mRNA
Triiodothyronine results in increased expression of THRSP mRNA

PMID:2721112 PMID:10357836 PMID:15953391 PMID:28478156 PMID:34571837

NCBI chr 1:151,723,415...151,727,740
Ensembl chr 1:151,723,086...151,728,075

G

transmembrane protein 184B

multiple interactions

[Triiodothyronine co-treated with Tetrachlorodibenzodioxin] results in increased expression of TMEM184B mRNA

NCBI chr 7:110,925,092...110,967,975
Ensembl chr 7:110,925,092...110,967,943

G

transmembrane protein 44

increases expression

Triiodothyronine results in increased expression of TMEM44 mRNA

NCBI chr11:70,181,120...70,216,958
Ensembl chr11:70,181,345...70,216,958

G

tumor necrosis factor

multiple interactions

[Triiodothyronine co-treated with Hexachlorocyclohexane] results in increased expression of TNF mRNA; [Triiodothyronine co-treated with Hexachlorocyclohexane] results in increased expression of TNF protein; Hexachlorocyclohexane inhibits the reaction [Triiodothyronine results in increased expression of TNF protein]; Triiodothyronine inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of TNF protein]; Triiodothyronine inhibits the reaction [Propylthiouracil results in increased expression of TNF mRNA]
THRA protein affects the reaction [Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased expression of TNF mRNA]]; THRA protein affects the reaction [Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased secretion of TNF protein]]; Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased expression of TNF mRNA]; Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased secretion of TNF protein]

PMID:15019085 PMID:29796989 PMID:32223187 PMID:36868496

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

TNF receptor superfamily member 9

multiple interactions
increases expression

4-OH-2',3,3',4',5'-pentachlorobiphenyl inhibits the reaction [Triiodothyronine results in increased expression of TNFRSF9 mRNA]; Polychlorinated Biphenyls inhibits the reaction [Triiodothyronine results in increased expression of TNFRSF9 mRNA]; Tetrachlorodibenzodioxin promotes the reaction [Triiodothyronine results in increased expression of TNFRSF9 mRNA]; Tetrachlorodibenzodioxin promotes the reaction [Triiodothyronine results in increased expression of TNFRSF9 protein]
Triiodothyronine results in increased expression of TNFRSF9 mRNA; Triiodothyronine results in increased expression of TNFRSF9 protein

NCBI chr 5:161,381,662...161,408,003
Ensembl chr 5:161,381,662...161,408,000

G

translocase of outer mitochondrial membrane 20

increases expression
multiple interactions

Triiodothyronine results in increased expression of TOMM20 protein
Chloroquine promotes the reaction [Triiodothyronine results in increased expression of TOMM20 protein]; Triiodothyronine promotes the reaction [bafilomycin A1 results in increased expression of TOMM20 protein]

NCBI chr19:54,925,197...54,935,188
Ensembl chr19:54,923,402...54,935,198

G

TNF receptor-associated factor 1

multiple interactions
increases expression

4-OH-2',3,3',4',5'-pentachlorobiphenyl inhibits the reaction [Triiodothyronine results in increased expression of TRAF1 mRNA]; Polychlorinated Biphenyls inhibits the reaction [Triiodothyronine results in increased expression of TRAF1 mRNA]; Tetrachlorodibenzodioxin promotes the reaction [Triiodothyronine results in increased expression of TRAF1 mRNA]; Tetrachlorodibenzodioxin promotes the reaction [Triiodothyronine results in increased expression of TRAF1 protein]
Triiodothyronine results in increased expression of TRAF1 mRNA; Triiodothyronine results in increased expression of TRAF1 protein

NCBI chr 3:18,222,024...18,242,163
Ensembl chr 3:18,222,054...18,241,807

G

tripartite motif-containing 46

increases expression

Triiodothyronine results in increased expression of TRIM46 mRNA

NCBI chr 2:174,641,494...174,654,237
Ensembl chr 2:174,641,496...174,654,141

G

thyroid stimulating hormone subunit beta

decreases expression
multiple interactions
increases secretion

Triiodothyronine results in decreased expression of TSHB mRNA
[Triiodothyronine co-treated with 2,2',4,4'-tetrabromodiphenyl ether] results in decreased expression of TSHB mRNA alternative form
TSHB protein results in increased secretion of Triiodothyronine

PMID:7827627 PMID:9092800 PMID:11288978 PMID:27420076 PMID:28167136

NCBI chr 2:190,224,676...190,229,559
Ensembl chr 2:190,224,676...190,229,559

G

tau tubulin kinase 1

increases expression

Triiodothyronine results in increased expression of TTBK1 mRNA

NCBI chr 9:14,493,166...14,538,372
Ensembl chr 9:14,493,389...14,535,774

G

titin

multiple interactions
affects expression

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Triiodothyronine affects the expression of TTN mRNA]; AKT1 protein affects the reaction [Triiodothyronine affects the expression of TTN mRNA]

NCBI chr 3:61,652,432...61,924,912
Ensembl chr 3:61,652,439...61,924,741

G

transthyretin

affects binding

Triiodothyronine binds to TTR protein

PMID:20804816 PMID:21517007

NCBI chr18:11,941,791...11,951,008
Ensembl chr18:11,943,789...11,951,008

G

uncoupling protein 1

multiple interactions
increases expression

(+)-JQ1 compound inhibits the reaction [[Triiodothyronine co-treated with Rosiglitazone co-treated with INS1 protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of UCP1 mRNA]; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of UCP1 mRNA; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of UCP1 protein; [Triiodothyronine co-treated with Rosiglitazone co-treated with INS1 protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of UCP1 mRNA
[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA]
Triiodothyronine results in increased expression of UCP1 mRNA; Triiodothyronine results in increased expression of UCP1 protein
[AVP protein co-treated with Norepinephrine] inhibits the reaction [Triiodothyronine inhibits the reaction [EGF protein results in decreased expression of UCP1 mRNA]]; [AVP protein co-treated with Norepinephrine] inhibits the reaction [Triiodothyronine promotes the reaction [FGF1 protein results in increased expression of UCP1 mRNA]]; [AVP protein co-treated with Norepinephrine] inhibits the reaction [Triiodothyronine promotes the reaction [FGF2 protein results in increased expression of UCP1 mRNA]]; [AVP protein co-treated with Norepinephrine] inhibits the reaction [Triiodothyronine results in increased expression of UCP1 mRNA]; [EGF protein co-treated with AVP protein co-treated with Norepinephrine co-treated with Triiodothyronine] results in decreased expression of UCP1 mRNA; [FGF1 protein co-treated with AVP protein co-treated with Norepinephrine co-treated with Triiodothyronine] results in decreased expression of UCP1 mRNA; [Triiodothyronine co-treated with Norepinephrine] results in increased expression of UCP1 mRNA; AVP protein inhibits the reaction [Triiodothyronine inhibits the reaction [EGF protein results in decreased expression of UCP1 mRNA]]; AVP protein inhibits the reaction [Triiodothyronine promotes the reaction [FGF1 protein results in increased expression of UCP1 mRNA]]; AVP protein inhibits the reaction [Triiodothyronine promotes the reaction [FGF2 protein results in increased expression of UCP1 mRNA]]; AVP protein inhibits the reaction [Triiodothyronine results in increased expression of UCP1 mRNA]; Triiodothyronine inhibits the reaction [EGF protein results in decreased expression of UCP1 mRNA]; Triiodothyronine promotes the reaction [FGF1 protein results in increased expression of UCP1 mRNA]; Triiodothyronine promotes the reaction [FGF2 protein results in increased expression of UCP1 mRNA]

PMID:11742803 PMID:26972250 PMID:30209975 PMID:33091441 PMID:33476690

NCBI chr19:24,808,782...24,816,853
Ensembl chr19:24,808,783...24,816,852

G

uncoupling protein 2

multiple interactions

THRA protein alternative form affects the reaction [Triiodothyronine promotes the reaction [Thiazolidinediones results in increased expression of UCP2]]; THRB protein alternative form affects the reaction [Triiodothyronine promotes the reaction [Thiazolidinediones results in increased expression of UCP2]]; Triiodothyronine promotes the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of UCP2 mRNA]; Triiodothyronine promotes the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of UCP2 protein]; Triiodothyronine promotes the reaction [Bezafibrate results in increased expression of UCP2 mRNA]; Triiodothyronine promotes the reaction [carboprostacyclin results in increased expression of UCP2 mRNA]; Triiodothyronine promotes the reaction [darglitazone results in increased expression of UCP2 mRNA]

PMID:12588052 PMID:25048947

NCBI chr 1:154,839,242...154,845,612
Ensembl chr 1:154,839,209...154,845,611

G

UDP-glucose ceramide glucosyltransferase

increases activity

Triiodothyronine results in increased activity of UGCG protein

NCBI chr 5:74,032,978...74,065,701
Ensembl chr 5:74,032,978...74,065,393

G

UDP glucuronosyltransferase family 1 member A1

decreases expression
multiple interactions

Triiodothyronine results in decreased expression of UGT1A1 mRNA
Vitamin A inhibits the reaction [Triiodothyronine results in decreased expression of UGT1A1 mRNA]

NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465

G

UDP glucuronosyltransferase family 1 member A6

increases expression
multiple interactions

Triiodothyronine results in increased expression of UGT1A6 mRNA
Vitamin A inhibits the reaction [Triiodothyronine results in increased expression of UGT1A6 mRNA]

NCBI chr 9:88,747,213...88,808,465
Ensembl chr 9:88,713,184...88,808,465

G

UTP20 small subunit processome component

multiple interactions

[Triiodothyronine co-treated with Tetrachlorodibenzodioxin] results in decreased expression of UTP20 mRNA

NCBI chr 7:23,134,630...23,215,639
Ensembl chr 7:23,134,637...23,215,632

G

voltage-dependent anion channel 1

increases expression
multiple interactions

Triiodothyronine results in increased expression of VDAC1 protein
Triiodothyronine promotes the reaction [bafilomycin A1 results in increased expression of VDAC1 protein]

NCBI chr10:36,532,306...36,559,642
Ensembl chr10:36,532,244...36,559,640

G

vascular endothelial growth factor A

multiple interactions

[BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of VEGFA mRNA

NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641

G

Wnt ligand secretion mediator

increases expression

Triiodothyronine results in increased expression of WLS mRNA

NCBI chr 2:248,931,885...249,047,248
Ensembl chr 2:248,931,903...249,048,298

G

Wnt family member 4

multiple interactions

[Triiodothyronine co-treated with Chlorpyrifos] results in decreased expression of WNT4 mRNA; [Triiodothyronine co-treated with Ethylenethiourea] results in decreased expression of WNT4 mRNA

NCBI chr 5:149,513,573...149,535,415
Ensembl chr 5:149,514,018...149,532,859

G

zinc finger CCCH-type containing 7B

decreases expression

Triiodothyronine results in decreased expression of ZC3H7B mRNA

NCBI chr 7:113,262,142...113,310,399
Ensembl chr 7:113,262,165...113,310,399

G

zinc finger protein 3

multiple interactions

[Triiodothyronine co-treated with Tetrachlorodibenzodioxin] results in decreased expression of ZNF3 mRNA

NCBI chr12:17,022,104...17,033,776
Ensembl chr12:17,022,279...17,033,709

G

zinc finger protein 664

increases expression

Triiodothyronine results in increased expression of ZNF664 mRNA

NCBI chr12:31,767,792...31,796,038
Ensembl chr12:31,767,720...31,796,545

G

zinc finger, MIZ-type containing 1

increases expression

Triiodothyronine results in increased expression of ZMIZ1 mRNA

NCBI chr16:1,027,083...1,232,616
Ensembl chr16:1,027,325...1,232,597

3,3'-diiodothyronine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

iodothyronine deiodinase 1

multiple interactions

[DIO1 protein results in increased metabolism of Triiodothyronine, Reverse] which results in increased abundance of 3,3'-diiodothyronine; Iodoacetates inhibits the reaction [[DIO1 protein results in increased metabolism of Triiodothyronine, Reverse] which results in increased abundance of 3,3'-diiodothyronine]

NCBI chr 5:122,074,285...122,090,983
Ensembl chr 5:122,074,279...122,090,970

G

sulfotransferase family 1A member 1

multiple interactions

3,3'-diiodothyronine inhibits the reaction [SULT1A1 protein results in increased sulfation of 4-nitrophenol]

NCBI chr 1:181,272,022...181,276,750
Ensembl chr 1:181,272,023...181,275,562

eflornithine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

MDM2 proto-oncogene

decreases expression

Eflornithine results in decreased expression of MDM2 mRNA

NCBI chr 7:53,290,660...53,315,205
Ensembl chr 7:53,290,664...53,314,915

G

phospholipase C, gamma 1

multiple interactions

[[Eflornithine results in decreased abundance of Polyamines] which results in decreased expression of and results in decreased activity of PLCG1 protein] which results in decreased abundance of Inositol 1,4,5-Trisphosphate; [Eflornithine results in decreased abundance of Polyamines] which results in decreased expression of and results in decreased activity of PLCG1 protein; [Eflornithine results in decreased abundance of Polyamines] which results in decreased expression of PLCG1 mRNA

NCBI chr 3:149,385,587...149,416,330
Ensembl chr 3:149,385,587...149,416,330

G

tumor protein p53

multiple interactions
increases expression
increases stability

Spermidine inhibits the reaction [Eflornithine results in increased expression of TP53 mRNA]
Eflornithine results in increased stability of TP53 mRNA; Eflornithine results in increased stability of TP53 protein

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

monoiodotyrosine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

iodotyrosine deiodinase

increases metabolic processing
multiple interactions

IYD protein results in increased metabolism of Monoiodotyrosine
1,2-dinitrobenzene inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; 1-monomyristin inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; 2,2'-dihydroxy-6,6'-dinaphthyldisulfide inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; 2,2'-methylenebis(4-methyl-6-tert-butylphenol) inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; 2,2'-methylenebis(ethyl-6-tert-butylphenol) inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; 2,4,5-trichlorophenol inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; 2,4-bis(alpha,alpha-dimethylbenzyl)phenol inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; 2,4-di-tert-butylphenol inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; 2,6-di-tert-butylphenol inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; 3,3',4',5-tetrachlorosalicylanilide inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; 3-nitrotyrosine inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; 4-nonylphenol inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; 4-octylphenol inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; 4-tert-octylphenol inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; 6-O-palmitoylascorbic acid inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; acid red 337 inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; Allura Red AC Dye inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; Benzalkonium Compounds inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; Bithionol inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; brilliant blue inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; Bromphenol Blue inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; C.I. Acid Red 114 inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; Cetrimonium inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; cetyl sulfate inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; Chlordecone inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; Chlorhexidine inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; Clomiphene inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; DDT inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; dexon (fungicide), sodium salt inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; di-2-(ethylhexyl)phosphoric acid inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; Dibutyl Phthalate inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; dichlone inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; Dichlorophen inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; Dicofol inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; didecyldimethylammonium inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; dinocap inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; Dioctyl Sulfosuccinic Acid inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; Direct Red 81 inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; dodecylbenzenesulfonic acid inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; dodecyltrimethylammonium inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; Eosine I Bluish inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; Eosine Yellowish-(YS) inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; Fast Green FCF inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; fluorophene inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; heptylparaben inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; isostearic acid inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; Kathon 930 inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; lauryl gallate inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; Linoleic Acid inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; Masoprocol inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; methyl linoleate inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; methylbenzethonium chloride inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; Methylene Blue inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; monoolein inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; morin inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; Myristic Acid inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; N-dodecylmorpholine inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; Nitrofurazone inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; o-Phthalaldehyde inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; octyl gallate inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; Oleic Acid inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; Palmitic Acid inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; perfluorodecanoic acid inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; perfluorooctane sulfonic acid inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; perfluoroundecanoic acid inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; Riboflavin inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; Sodium Dodecyl Sulfate inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; sodium laureth sulfate inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; Sodium Tetradecyl Sulfate inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; Tamoxifen inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; tetrabromobisphenol A inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; tetrachlorodian inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; tetradecyltrimethylammonium inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; texapon TH inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; Tinopal CBS-X inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; tribromsalan inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; Triclosan inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; triflumizol inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; trioctylmethylammonium inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]; Troglitazone inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]

NCBI chr 1:40,003,999...40,019,323
Ensembl chr 1:40,004,041...40,019,319

thyroxine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

aminoadipate aminotransferase

affects activity
multiple interactions

Thyroxine affects the activity of AADAT protein
Thyroxine inhibits the reaction [Propylthiouracil results in decreased activity of AADAT protein]

NCBI chr16:29,509,392...29,544,332
Ensembl chr16:29,509,394...29,544,332

G

ATP binding cassette subfamily C member 2

decreases abundance

ABCC2 results in decreased abundance of Thyroxine

NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238

G

aryl hydrocarbon receptor

multiple interactions

AHR affects the reaction [2,4,6-triphenyl-1-hexene results in increased abundance of Thyroxine]

NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568

G

AKT serine/threonine kinase 1

multiple interactions

Thyroxine inhibits the reaction [Propylthiouracil results in increased expression of AKT1 mRNA]; Thyroxine inhibits the reaction [Propylthiouracil results in increased expression of and results in increased phosphorylation of AKT1 protein]; Thyroxine inhibits the reaction [Propylthiouracil results in increased phosphorylation of AKT1 protein]

PMID:35101570 PMID:37295576

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

albumin

affects binding
multiple interactions

Thyroxine binds to ALB protein
2,2',4,5'-tetrabromodiphenyl ether metabolite inhibits the reaction [Thyroxine binds to ALB protein]; Flame Retardants analog inhibits the reaction [Thyroxine binds to ALB protein]

PMID:20039755 PMID:21517007 PMID:29283575

NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836

G

anti-Mullerian hormone

multiple interactions

Thyroxine affects the reaction [Propylthiouracil affects the expression of AMH mRNA]

NCBI chr 7:8,906,776...8,909,192
Ensembl chr 7:8,906,836...8,909,282

G

apolipoprotein D

increases expression

Thyroxine results in increased expression of APOD mRNA; Thyroxine results in increased expression of APOD protein

NCBI chr11:69,431,261...69,452,306
Ensembl chr11:69,431,260...69,452,305

G

amyloid beta precursor protein

decreases cleavage
decreases expression

Thyroxine results in decreased cleavage of APP protein
Thyroxine results in decreased expression of APP mRNA; Thyroxine results in decreased expression of APP protein

NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561

G

BCL2-associated agonist of cell death

multiple interactions
decreases expression

[nano-diamino-tetrac co-treated with Resveratrol] inhibits the reaction [Thyroxine results in decreased expression of BAD mRNA]; Resveratrol inhibits the reaction [Thyroxine results in decreased expression of BAD mRNA]; Thyroxine inhibits the reaction [Resveratrol results in increased expression of BAD mRNA]

PMID:31336132 PMID:31883986

NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823

G

BCL2, apoptosis regulator

multiple interactions

Thyroxine inhibits the reaction [Propylthiouracil results in increased expression of BCL2 protein]

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

catalase

multiple interactions
decreases activity
decreases expression

[Curcumin co-treated with Vitamin E] inhibits the reaction [Thyroxine results in decreased expression of CAT mRNA]; [Vitamin E co-treated with Curcumin] inhibits the reaction [Thyroxine results in decreased activity of CAT protein]; arotinolol promotes the reaction [Thyroxine results in decreased expression of CAT protein]; Atenolol promotes the reaction [Thyroxine results in decreased expression of CAT protein]; Curcumin inhibits the reaction [Thyroxine results in decreased expression of CAT mRNA]; Curcumin inhibits the reaction [Thyroxine results in decreased expression of CAT protein]; Thyroxine inhibits the reaction [Propylthiouracil results in decreased activity of CAT protein]; Vitamin E inhibits the reaction [Thyroxine results in decreased activity of CAT protein]; Vitamin E inhibits the reaction [Thyroxine results in decreased expression of CAT protein]
Thyroxine results in decreased expression of CAT mRNA; Thyroxine results in decreased expression of CAT protein

PMID:2575990 PMID:18723006 PMID:19914224 PMID:34047416

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

cyclin D1

increases expression
multiple interactions

Thyroxine results in increased expression of CCND1 mRNA
[Resveratrol co-treated with nano-diamino-tetrac] inhibits the reaction [Thyroxine results in increased expression of CCND1 mRNA]; nano-diamino-tetrac inhibits the reaction [Thyroxine results in increased expression of CCND1 mRNA]; Resveratrol inhibits the reaction [Thyroxine results in increased expression of CCND1 mRNA]

PMID:31336132 PMID:31883986

NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602

G

CD274 molecule

increases expression
multiple interactions

Thyroxine results in increased expression of CD274 mRNA; Thyroxine results in increased expression of CD274 protein; Thyroxine results in increased expression of PDL1 mRNA; Thyroxine results in increased expression of PDL1 protein
[Resveratrol co-treated with nano-diamino-tetrac] inhibits the reaction [Thyroxine results in increased expression of PDL1 mRNA]; nano-diamino-tetrac inhibits the reaction [Thyroxine results in increased expression of CD274 mRNA]; nano-diamino-tetrac inhibits the reaction [Thyroxine results in increased expression of CD274 protein]; nano-diamino-tetrac inhibits the reaction [Thyroxine results in increased expression of PDL1 mRNA]; NSC 74859 inhibits the reaction [Thyroxine results in increased expression of PDL1 protein]; Resveratrol inhibits the reaction [Thyroxine results in increased expression of PDL1 mRNA]; Resveratrol inhibits the reaction [Thyroxine results in increased expression of PDL1 protein]

PMID:29960019 PMID:31336132 PMID:31883986

NCBI chr 1:227,116,674...227,137,379
Ensembl chr 1:227,116,649...227,134,450

G

cell death-inducing DFFA-like effector a

multiple interactions

[acetyl methyl tetramethyl tetralin co-treated with Biotin co-treated with Pantothenic Acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Thyroxine co-treated with TF protein] results in decreased expression of CIDEA mRNA

NCBI chr18:60,894,917...60,920,485
Ensembl chr18:60,894,874...60,920,481

G

cell death-inducing DFFA-like effector c

multiple interactions

[acetyl methyl tetramethyl tetralin co-treated with Biotin co-treated with Pantothenic Acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Thyroxine co-treated with TF protein] results in increased expression of CIDEC mRNA; [quinoxyfen co-treated with Biotin co-treated with Pantothenic Acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Thyroxine co-treated with TF protein] results in increased expression of CIDEC mRNA

NCBI chr 4:146,569,288...146,582,173
Ensembl chr 4:146,569,289...146,582,173

G

cytochrome P450, family 2, subfamily c, polypeptide 79

decreases activity

Thyroxine results in decreased activity of CYP2C8 protein

G

cytochrome P450, family 3, subfamily a, polypeptide 2

multiple interactions

[Thyroxine results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

G

cytochrome P450 family 8 subfamily B member 1

decreases expression

Thyroxine results in decreased expression of CYP8B1 mRNA

NCBI chr 8:121,578,123...121,580,093
Ensembl chr 8:121,557,062...121,580,166

G

decorin

decreases expression

Thyroxine results in decreased expression of DCN mRNA

NCBI chr 7:32,281,252...32,321,291
Ensembl chr 7:32,281,252...32,321,270

G

iodothyronine deiodinase 1

affects abundance
multiple interactions
increases expression
affects metabolic processing
increases metabolic processing

DIO1 gene SNP affects the abundance of Thyroxine
2,2',4,4'-tetrabromodiphenyl ether inhibits the reaction [Thyroxine results in increased expression of DIO1 mRNA]
DIO1 protein affects the metabolism of Thyroxine
[DIO1 protein results in increased metabolism of Thyroxine] which results in increased abundance of Triiodothyronine; Iodoacetates inhibits the reaction [[DIO1 protein results in increased metabolism of Thyroxine] which results in increased abundance of Triiodothyronine]

PMID:15254343 PMID:17105838 PMID:21565810 PMID:27420076

NCBI chr 5:122,074,285...122,090,983
Ensembl chr 5:122,074,279...122,090,970

G

iodothyronine deiodinase 2

multiple interactions
decreases expression
decreases activity
increases metabolic processing
affects metabolic processing

2,2',4,4',5-brominated diphenyl ether inhibits the reaction [[DIO2 protein results in increased metabolism of Thyroxine] which results in increased chemical synthesis of Triiodothyronine]; 2,2',4,4',5-brominated diphenyl ether metabolite inhibits the reaction [[DIO2 protein results in increased metabolism of Thyroxine] which results in increased chemical synthesis of Triiodothyronine]; 2,2',4,4'-tetrabromodiphenyl ether metabolite inhibits the reaction [[DIO2 protein results in increased metabolism of Thyroxine] which results in increased chemical synthesis of Triiodothyronine]; [Aurothioglucose results in decreased activity of DIO2 protein] which affects the metabolism of Thyroxine; [DIO2 protein results in increased metabolism of Thyroxine] which results in increased chemical synthesis of Triiodothyronine; [xanthohumol results in decreased activity of DIO2 protein] which affects the metabolism of Thyroxine; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Thyroxine results in decreased activity of DIO2 protein]; lactacystin inhibits the reaction [Thyroxine results in decreased activity of DIO2 protein]; Thyroxine results in decreased expression of and results in decreased activity of DIO2 protein
2,2',4,4'-tetrabromodiphenyl ether inhibits the reaction [Thyroxine results in decreased expression of DIO2 mRNA]
DIO2 protein mutant form affects the metabolism of Thyroxine

PMID:11108274 PMID:11425850 PMID:16728495 PMID:17615150 PMID:25962824 More...

NCBI chr 6:109,665,523...109,679,809
Ensembl chr 6:109,665,523...109,679,809

G

iodothyronine deiodinase 3

increases activity
multiple interactions

Thyroxine results in increased activity of DIO3 protein
Hydrogen Peroxide promotes the reaction [Thyroxine results in increased activity of DIO3 protein]

NCBI chr 6:129,285,747...129,287,608
Ensembl chr 6:129,285,749...129,286,660

G

dentin matrix acidic phosphoprotein 1

increases expression

Thyroxine results in increased expression of DMP1 mRNA

NCBI chr14:5,528,441...5,542,078
Ensembl chr14:5,528,431...5,539,323

G

dual oxidase 1

decreases expression

Thyroxine results in decreased expression of DUOX1 protein

NCBI chr 3:109,260,526...109,295,588
Ensembl chr 3:109,262,397...109,295,563

G

dual oxidase 2

decreases expression

Thyroxine results in decreased expression of DUOX2 protein

NCBI chr 3:109,223,809...109,247,023
Ensembl chr 3:109,226,924...109,245,902

G

fibroblast growth factor 1

increases expression

Thyroxine results in increased expression of FGF1 mRNA

NCBI chr18:30,686,555...30,772,667
Ensembl chr18:30,686,581...30,772,357

G

fibroblast growth factor 2

increases expression

Thyroxine results in increased expression of FGF2 mRNA

NCBI chr 2:120,236,328...120,290,673
Ensembl chr 2:120,236,328...120,291,221

G

Fms related receptor tyrosine kinase 1

decreases expression

Thyroxine results in decreased expression of FLT1 mRNA

NCBI chr12:7,296,899...7,468,626
Ensembl chr12:7,297,292...7,468,626

G

growth associated protein 43

increases expression
multiple interactions

Thyroxine results in increased expression of GAP43 mRNA
Thyroxine inhibits the reaction [Ethanol results in decreased expression of GAP43 mRNA]

NCBI chr11:58,376,371...58,470,047
Ensembl chr11:58,376,371...58,470,045

G

growth hormone 1

decreases abundance
multiple interactions

GH1 protein results in decreased abundance of Thyroxine
[2,2',4,4'-tetrabromodiphenyl ether co-treated with Thyroxine] results in increased expression of GH mRNA

PMID:17311540 PMID:17324600 PMID:27420076

NCBI chr10:91,228,102...91,230,079
Ensembl chr10:91,228,103...91,230,078

G

glycerol-3-phosphate dehydrogenase 2

multiple interactions

Ipodate inhibits the reaction [Thyroxine results in increased activity of GPD2 protein]; Propylthiouracil inhibits the reaction [Thyroxine results in increased activity of GPD2 protein]

NCBI chr 3:41,800,552...41,937,729
Ensembl chr 3:41,801,930...41,936,901

G

glutamic--pyruvic transaminase

multiple interactions

Thyroxine inhibits the reaction [Propylthiouracil results in increased expression of GPT protein]

NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494

G

glutathione peroxidase 1

multiple interactions
increases activity
decreases activity
increases expression
decreases expression

[Curcumin co-treated with Vitamin E] inhibits the reaction [Thyroxine results in increased expression of GPX1 protein]; Curcumin inhibits the reaction [Thyroxine results in decreased expression of GPX1 mRNA]; Vitamin E inhibits the reaction [Thyroxine results in decreased expression of GPX1 mRNA]
Thyroxine results in increased activity of GPX1 protein
Thyroxine results in decreased activity of GPX1 protein

NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024

G

glutathione-disulfide reductase

multiple interactions
decreases activity
decreases expression

[Curcumin co-treated with Vitamin E] inhibits the reaction [Thyroxine results in decreased expression of GSR mRNA]; Curcumin inhibits the reaction [Thyroxine results in decreased expression of GSR mRNA]; Vitamin E inhibits the reaction [Thyroxine results in decreased expression of GSR mRNA]
Thyroxine results in decreased activity of GSR protein
Thyroxine results in decreased expression of GSR mRNA; Thyroxine results in decreased expression of GSR protein

NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661

G

hes family bHLH transcription factor 1

multiple interactions

[Propylthiouracil results in increased abundance of Thyroxine] which results in increased expression of HES1 mRNA

NCBI chr11:70,705,763...70,708,176
Ensembl chr11:70,705,764...70,708,192

G

hes family bHLH transcription factor 5

multiple interactions

[Propylthiouracil results in increased abundance of Thyroxine] which results in increased expression of HES5 mRNA

NCBI chr 5:165,522,138...165,523,684
Ensembl chr 5:165,522,234...165,523,001

G

HR, lysine demethylase and nuclear receptor corepressor

increases expression

Thyroxine results in increased expression of HR mRNA

NCBI chr15:45,626,835...45,646,313
Ensembl chr15:45,626,835...45,646,313

G

HRas proto-oncogene, GTPase

multiple interactions

Thyroxine inhibits the reaction [Propylthiouracil results in increased expression of HRAS protein]

NCBI chr 1:196,290,127...196,299,823
Ensembl chr 1:196,296,263...196,300,615

G

HtrA serine peptidase 1

increases expression

Thyroxine results in increased expression of HTRA1 mRNA

NCBI chr 1:185,497,815...185,547,380
Ensembl chr 1:185,497,735...185,547,379

G

interferon gamma

increases expression

Thyroxine results in increased expression of IFNG mRNA; Thyroxine results in increased expression of IFNG protein

NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375

G

insulin-like growth factor 1

increases expression

Thyroxine results in increased expression of IGF1 mRNA

NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296

G

insulin-like growth factor 1 receptor

multiple interactions
increases expression

Vitamin E inhibits the reaction [Thyroxine results in increased expression of IGF1R protein]

NCBI chr 1:121,549,831...121,838,548
Ensembl chr 1:121,550,743...121,831,777

G

interleukin 10

increases expression

Thyroxine results in increased expression of IL10 mRNA

NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313

G

interleukin 1 beta

multiple interactions
increases expression

NSC 74859 inhibits the reaction [Thyroxine results in increased expression of IL1B mRNA]

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 6

multiple interactions

Thyroxine inhibits the reaction [Propylthiouracil results in increased expression of IL6 protein]

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

insulin 1

multiple interactions

[acetyl methyl tetramethyl tetralin co-treated with Biotin co-treated with Pantothenic Acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Thyroxine co-treated with TF protein] results in decreased expression of CIDEA mRNA; [acetyl methyl tetramethyl tetralin co-treated with Biotin co-treated with Pantothenic Acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Thyroxine co-treated with TF protein] results in decreased expression of SDHA protein; [acetyl methyl tetramethyl tetralin co-treated with Biotin co-treated with Pantothenic Acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Thyroxine co-treated with TF protein] results in increased expression of CIDEC mRNA; [quinoxyfen co-treated with Biotin co-treated with Pantothenic Acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Thyroxine co-treated with TF protein] results in decreased expression of SDHA protein; [quinoxyfen co-treated with Biotin co-treated with Pantothenic Acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Thyroxine co-treated with TF protein] results in increased expression of CIDEC mRNA

NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536

G

integrin subunit alpha V

multiple interactions

[Methamphetamine co-treated with Thyroxine] results in increased expression of ITGAV protein

NCBI chr 3:68,838,514...68,926,653
Ensembl chr 3:68,838,189...68,926,639

G

integrin subunit beta 3

multiple interactions

ITGB3 inhibits the reaction [bisphenol A inhibits the reaction [Thyroxine inhibits the reaction [NCOR1 protein binds to and results in decreased activity of THRB protein]]]; ITGB3 inhibits the reaction [bisphenol A inhibits the reaction [Thyroxine inhibits the reaction [NCOR2 protein binds to and results in decreased activity of THRB protein]]]

NCBI chr10:89,509,917...89,564,679
Ensembl chr10:89,509,989...89,564,679

G

kinase insert domain receptor

increases expression
decreases expression

Thyroxine results in increased expression of KDR mRNA; Thyroxine results in increased expression of KDR protein
Thyroxine results in decreased expression of KDR mRNA

PMID:25298361 PMID:25499719

NCBI chr14:32,217,871...32,261,018
Ensembl chr14:32,217,871...32,261,018

G

kynurenine aminotransferase 1

multiple interactions
affects activity

Thyroxine inhibits the reaction [Propylthiouracil results in decreased activity of KYAT1 protein]
Thyroxine affects the activity of KYAT1 protein

NCBI chr 3:13,459,598...13,493,308
Ensembl chr 3:13,459,591...13,493,355

G

mitogen activated protein kinase 1

multiple interactions
increases phosphorylation
affects localization

NSC 74859 inhibits the reaction [Thyroxine results in increased phosphorylation of MAPK1 protein]
Thyroxine affects the localization of MAPK1 protein
tetraiodothyroacetic acid inhibits the reaction [Thyroxine affects the localization of MAPK1 protein]

PMID:17984113 PMID:31336132

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

multiple interactions
increases phosphorylation
affects localization

NSC 74859 inhibits the reaction [Thyroxine results in increased phosphorylation of MAPK3 protein]
Thyroxine affects the localization of MAPK3 protein
tetraiodothyroacetic acid inhibits the reaction [Thyroxine affects the localization of MAPK3 protein]

PMID:17984113 PMID:31336132

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

minichromosome maintenance complex component 7

increases expression

Thyroxine results in increased expression of MCM7 protein

NCBI chr12:17,042,207...17,049,470
Ensembl chr12:17,042,212...17,050,063

G

macrophage migration inhibitory factor

increases expression
affects expression

Thyroxine results in increased expression of MIF protein
Thyroxine affects the expression of MIF mRNA

NCBI chr20:12,790,919...12,791,784
Ensembl chr20:12,790,902...12,799,504

G

matrix metallopeptidase 2

increases expression

Thyroxine results in increased expression of MMP2 mRNA

NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870

G

matrix metallopeptidase 9

increases expression

Thyroxine results in increased expression of MMP9 mRNA

NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120

G

nuclear receptor coactivator 2

multiple interactions

Thyroxine promotes the reaction [THRA protein binds to NCOA2 protein]; Thyroxine promotes the reaction [THRB protein binds to NCOA2 protein]

NCBI chr 5:5,835,642...6,069,693
Ensembl chr 5:5,835,706...6,067,451

G

nuclear receptor co-repressor 1

multiple interactions

2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Thyroxine inhibits the reaction [THRB protein binds to NCOR1 protein]]; AG 1879 inhibits the reaction [Thyroxine inhibits the reaction [THRB protein binds to NCOR1 protein]]; bisphenol A inhibits the reaction [Thyroxine inhibits the reaction [NCOR1 protein binds to and results in decreased activity of THRB protein]]; bisphenol A inhibits the reaction [Thyroxine inhibits the reaction [THRB protein binds to NCOR1 protein]]; ITGB3 inhibits the reaction [bisphenol A inhibits the reaction [Thyroxine inhibits the reaction [NCOR1 protein binds to and results in decreased activity of THRB protein]]]; SRC inhibits the reaction [bisphenol A inhibits the reaction [Thyroxine inhibits the reaction [NCOR1 protein binds to and results in decreased activity of THRB protein]]]; tetraiodothyroacetic acid inhibits the reaction [Thyroxine inhibits the reaction [THRB protein binds to NCOR1 protein]]; Thyroxine inhibits the reaction [NCOR1 protein binds to and results in decreased activity of THRB protein]; Thyroxine inhibits the reaction [THRB protein binds to NCOR1 protein]

NCBI chr10:46,999,536...47,142,294
Ensembl chr10:46,999,536...47,141,032

G

nuclear receptor co-repressor 2

multiple interactions

2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Thyroxine inhibits the reaction [THRB protein binds to NCOR2 protein]]; AG 1879 inhibits the reaction [Thyroxine inhibits the reaction [THRB protein binds to NCOR2 protein]]; bisphenol A inhibits the reaction [Thyroxine inhibits the reaction [THRB protein binds to NCOR2 protein]]; ITGB3 inhibits the reaction [bisphenol A inhibits the reaction [Thyroxine inhibits the reaction [NCOR2 protein binds to and results in decreased activity of THRB protein]]]; SRC inhibits the reaction [bisphenol A inhibits the reaction [Thyroxine inhibits the reaction [NCOR2 protein binds to and results in decreased activity of THRB protein]]]; tetraiodothyroacetic acid inhibits the reaction [Thyroxine inhibits the reaction [THRB protein binds to NCOR2 protein]]; Thyroxine inhibits the reaction [THRB protein binds to NCOR2 protein]

NCBI chr12:31,466,418...31,628,319
Ensembl chr12:31,466,412...31,628,319

G

nitric oxide synthase 1

increases expression

Thyroxine results in increased expression of NOS1 protein

NCBI chr12:38,615,111...38,795,492
Ensembl chr12:38,626,714...38,710,945

G

nitric oxide synthase 2

increases expression

Thyroxine results in increased expression of NOS2 protein

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

nitric oxide synthase 3

increases expression

Thyroxine results in increased expression of NOS3 mRNA; Thyroxine results in increased expression of NOS3 protein

NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166

G

nuclear receptor subfamily 1, group I, member 2

increases activity
multiple interactions

Thyroxine results in increased activity of NR1I2 protein
[Thyroxine results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA

NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658

G

nuclear receptor subfamily 1, group I, member 3

affects metabolic processing

NR1I3 protein affects the metabolism of Thyroxine

NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906

G

nuclear receptor subfamily 3, group C, member 1

multiple interactions
increases expression

Thyroxine inhibits the reaction [Ethanol results in decreased expression of NR3C1 mRNA]
Thyroxine results in increased expression of NR3C1 mRNA

NCBI chr18:31,271,681...31,393,320
Ensembl chr18:31,271,681...31,393,375

G

ornithine decarboxylase 1

multiple interactions

Ipodate inhibits the reaction [Thyroxine results in increased activity of ODC1 protein]; Propylthiouracil inhibits the reaction [Thyroxine results in increased activity of ODC1 protein]

NCBI chr 6:40,329,831...40,336,444
Ensembl chr 6:40,329,964...40,336,440

G

proprotein convertase subtilisin/kexin type 2

decreases expression

Thyroxine results in decreased expression of PCSK2 mRNA

NCBI chr 3:130,880,422...131,183,127
Ensembl chr 3:130,880,422...131,183,127

G

placental growth factor

increases expression

Thyroxine results in increased expression of PGF mRNA

NCBI chr 6:104,816,102...104,826,685
Ensembl chr 6:104,816,104...104,826,685

G

phosphate regulating endopeptidase X-linked

increases expression

Thyroxine results in increased expression of PHEX mRNA

NCBI chr X:37,607,553...37,856,183
Ensembl chr X:37,610,760...37,854,469

G

peripheral myelin protein 22

increases expression

Thyroxine results in increased expression of PMP22 mRNA

NCBI chr10:47,795,709...47,825,715
Ensembl chr10:47,795,709...47,825,714

G

cytochrome p450 oxidoreductase

increases expression

Thyroxine results in increased expression of POR mRNA

NCBI chr12:20,951,058...20,999,198
Ensembl chr12:20,951,058...20,999,245

G

peroxisome proliferator-activated receptor gamma

multiple interactions

Thyroxine inhibits the reaction [Triclosan results in decreased expression of PPARG protein]

NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468

G

prostaglandin-endoperoxide synthase 2

multiple interactions
increases expression
decreases expression

Thyroxine inhibits the reaction [resveratrol affects the localization of PTGS2 protein]
Thyroxine results in increased expression of PTGS2 protein
Thyroxine results in decreased expression of PTGS2 mRNA
[Resveratrol co-treated with nano-diamino-tetrac] promotes the reaction [Thyroxine results in decreased expression of PTGS2 mRNA]; nano-diamino-tetrac promotes the reaction [Thyroxine results in decreased expression of PTGS2 mRNA]; Resveratrol inhibits the reaction [Thyroxine results in decreased expression of PTGS2 mRNA]; Thyroxine inhibits the reaction [Resveratrol affects the localization of PTGS2 protein]; Thyroxine inhibits the reaction [Resveratrol results in increased expression of PTGS2 mRNA]

PMID:17984113 PMID:25298361 PMID:31336132 PMID:31883986

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

RAP1A, member of RAS oncogene family

multiple interactions

RAP1A protein promotes the reaction [mono-(2-ethylhexyl)phthalate results in decreased expression of Thyroxine]

NCBI chr 2:193,208,631...193,286,513
Ensembl chr 2:193,208,635...193,286,501

G

retinoid X receptor alpha

affects binding

Thyroxine binds to RXRA protein

NCBI chr 3:10,989,832...11,076,366
Ensembl chr 3:10,989,832...11,073,712

G

succinate dehydrogenase complex flavoprotein subunit A

multiple interactions

[acetyl methyl tetramethyl tetralin co-treated with Biotin co-treated with Pantothenic Acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Thyroxine co-treated with TF protein] results in decreased expression of SDHA protein; [quinoxyfen co-treated with Biotin co-treated with Pantothenic Acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Thyroxine co-treated with TF protein] results in decreased expression of SDHA protein

NCBI chr 1:28,935,965...28,960,936
Ensembl chr 1:28,940,164...28,961,535

G

semaphorin 7A (John Milton Hagen blood group)

increases expression

Thyroxine results in increased expression of SEMA7A mRNA

NCBI chr 8:58,348,448...58,370,536
Ensembl chr 8:58,348,448...58,370,536

G

serpin family A member 7

multiple interactions
affects binding

3,5-dichlorobiphenyl metabolite inhibits the reaction [Thyroxine binds to SERPINA7 protein]; bisphenol A inhibits the reaction [Thyroxine binds to SERPINA7 protein]; tetrabromobisphenol A inhibits the reaction [Thyroxine binds to SERPINA7 protein]; tetrachlorodian inhibits the reaction [Thyroxine binds to SERPINA7 protein]

PMID:16478101 PMID:20804816 PMID:21517007 PMID:27528273

NCBI chr X:102,663,242...102,722,319
Ensembl chr X:102,663,405...102,669,040

G

sonic hedgehog signaling molecule

increases expression

Thyroxine results in increased expression of SHH mRNA

NCBI chr 4:6,954,017...6,963,170
Ensembl chr 4:6,954,017...6,963,170

G

sirtuin 1

increases expression

Thyroxine results in increased expression of SIRT1 protein

NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260

G

solute carrier family 2 member 4

multiple interactions

Thyroxine inhibits the reaction [Triclosan results in decreased expression of SLC2A4 protein]

NCBI chr10:54,666,015...54,671,581
Ensembl chr10:54,666,015...54,671,565

G

solute carrier family 30, member 10

decreases chemical synthesis

SLC30A10 gene mutant form results in decreased chemical synthesis of Thyroxine

NCBI chr13:96,998,143...97,048,076
Ensembl chr13:96,998,143...97,009,103

G

solute carrier family 5 member 5

decreases expression

Thyroxine results in decreased expression of SLC5A5 protein

NCBI chr16:18,546,709...18,556,698
Ensembl chr16:18,546,709...18,556,697

G

superoxide dismutase 1

multiple interactions
increases expression
increases activity
decreases activity
decreases expression

[Curcumin co-treated with Vitamin E] inhibits the reaction [Thyroxine results in decreased expression of SOD1 mRNA]; [Curcumin co-treated with Vitamin E] inhibits the reaction [Thyroxine results in increased activity of SOD1 protein]; [Curcumin co-treated with Vitamin E] promotes the reaction [Thyroxine results in decreased activity of SOD1 protein]; Atenolol promotes the reaction [Thyroxine results in decreased expression of SOD1 protein]; Curcumin inhibits the reaction [Thyroxine results in decreased expression of SOD1 mRNA]; Curcumin inhibits the reaction [Thyroxine results in increased activity of SOD1 protein]; Curcumin promotes the reaction [Thyroxine results in decreased activity of SOD1 protein]; Thyroxine inhibits the reaction [Zinc deficiency results in increased activity of SOD1 protein]; Vitamin E inhibits the reaction [Thyroxine results in decreased expression of SOD1 mRNA]; Vitamin E inhibits the reaction [Thyroxine results in decreased expression of SOD1 protein]; Vitamin E inhibits the reaction [Thyroxine results in increased activity of SOD1 protein]; Vitamin E inhibits the reaction [Thyroxine results in increased expression of SOD1 protein]; Vitamin E promotes the reaction [Thyroxine results in decreased activity of SOD1 protein]
Thyroxine results in decreased expression of SOD1 mRNA; Thyroxine results in decreased expression of SOD1 protein

PMID:2575990 PMID:10381190 PMID:17447016 PMID:19914224

NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249

G

superoxide dismutase 2

multiple interactions
decreases activity
decreases expression
increases expression

[Vitamin E co-treated with Curcumin] inhibits the reaction [Thyroxine results in decreased expression of SOD2 mRNA]; Atenolol inhibits the reaction [Thyroxine results in increased expression of SOD2 protein]; Curcumin inhibits the reaction [Thyroxine results in decreased activity of SOD2 protein]; Curcumin promotes the reaction [Thyroxine results in increased expression of SOD2 protein]; Vitamin E inhibits the reaction [Thyroxine results in decreased expression of SOD2 mRNA]; Vitamin E promotes the reaction [Thyroxine results in increased expression of SOD2 protein]

PMID:2575990 PMID:19914224

NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189

G

SRC proto-oncogene, non-receptor tyrosine kinase

multiple interactions

SRC inhibits the reaction [bisphenol A inhibits the reaction [Thyroxine inhibits the reaction [NCOR1 protein binds to and results in decreased activity of THRB protein]]]; SRC inhibits the reaction [bisphenol A inhibits the reaction [Thyroxine inhibits the reaction [NCOR2 protein binds to and results in decreased activity of THRB protein]]]

NCBI chr 3:146,091,969...146,139,492
Ensembl chr 3:146,091,841...146,139,476

G

signal transducer and activator of transcription 3

multiple interactions
increases phosphorylation

NSC 74859 inhibits the reaction [Thyroxine results in increased phosphorylation of STAT3 protein]

NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057

G

sulfotransferase family 1A member 1

affects sulfation
multiple interactions
increases sulfation

SULT1A1 gene polymorphism affects the sulfation of Thyroxine
Thyroxine inhibits the reaction [SULT1A1 protein results in increased sulfation of 4-nitrophenol]
SULT1A1 protein results in increased sulfation of Thyroxine

PMID:11739018 PMID:15531517

NCBI chr 1:181,272,022...181,276,750
Ensembl chr 1:181,272,023...181,275,562

G

sulfotransferase family 4A, member 1

increases metabolic processing

SULT4A1 protein results in increased metabolism of Thyroxine

NCBI chr 7:115,216,066...115,240,156
Ensembl chr 7:115,216,066...115,240,085

G

synapsin I

multiple interactions

Thyroxine inhibits the reaction [Phenytoin results in decreased expression of SYN1 mRNA]

NCBI chr X:1,172,208...1,227,400
Ensembl chr X:1,172,208...1,227,396

G

synaptophysin

multiple interactions

Thyroxine inhibits the reaction [Phenytoin results in decreased expression of SYP mRNA]

NCBI chr X:14,849,444...14,864,553
Ensembl chr X:14,849,444...14,864,745

G

transferrin

multiple interactions

[acetyl methyl tetramethyl tetralin co-treated with Biotin co-treated with Pantothenic Acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Thyroxine co-treated with TF protein] results in decreased expression of CIDEA mRNA; [acetyl methyl tetramethyl tetralin co-treated with Biotin co-treated with Pantothenic Acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Thyroxine co-treated with TF protein] results in decreased expression of SDHA protein; [acetyl methyl tetramethyl tetralin co-treated with Biotin co-treated with Pantothenic Acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Thyroxine co-treated with TF protein] results in increased expression of CIDEC mRNA; [quinoxyfen co-treated with Biotin co-treated with Pantothenic Acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Thyroxine co-treated with TF protein] results in decreased expression of SDHA protein; [quinoxyfen co-treated with Biotin co-treated with Pantothenic Acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Thyroxine co-treated with TF protein] results in increased expression of CIDEC mRNA

NCBI chr 8:103,789,780...103,816,487
Ensembl chr 8:103,767,995...103,816,511

G

transforming growth factor, beta 1

multiple interactions
increases expression

NSC 74859 inhibits the reaction [Thyroxine results in increased expression of TGFB1 mRNA]; Resveratrol inhibits the reaction [Thyroxine results in increased expression of TGFB1 mRNA]

NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847

G

thyroid hormone receptor alpha

affects binding
multiple interactions
increases expression

Thyroxine binds to THRA protein
Thyroxine promotes the reaction [THRA protein binds to NCOA2 protein]
Thyroxine results in increased expression of THRA mRNA
[bisphenol A co-treated with Estradiol co-treated with Thyroxine] results in increased expression of THRA mRNA; [bisphenol A co-treated with Thyroxine] results in increased expression of THRA mRNA

PMID:23112079 PMID:23402801 PMID:27993100 PMID:31566444

NCBI chr10:83,701,885...83,729,408
Ensembl chr10:83,700,755...83,729,936

G

thyroid hormone receptor beta

multiple interactions
decreases expression
increases expression
increases activity
affects binding

2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Thyroxine inhibits the reaction [THRB protein binds to NCOR1 protein]]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Thyroxine inhibits the reaction [THRB protein binds to NCOR2 protein]]; AG 1879 inhibits the reaction [Thyroxine inhibits the reaction [THRB protein binds to NCOR1 protein]]; AG 1879 inhibits the reaction [Thyroxine inhibits the reaction [THRB protein binds to NCOR2 protein]]; bisphenol A inhibits the reaction [Thyroxine inhibits the reaction [NCOR1 protein binds to and results in decreased activity of THRB protein]]; bisphenol A inhibits the reaction [Thyroxine inhibits the reaction [THRB protein binds to NCOR1 protein]]; bisphenol A inhibits the reaction [Thyroxine inhibits the reaction [THRB protein binds to NCOR2 protein]]; ITGB3 inhibits the reaction [bisphenol A inhibits the reaction [Thyroxine inhibits the reaction [NCOR1 protein binds to and results in decreased activity of THRB protein]]]; ITGB3 inhibits the reaction [bisphenol A inhibits the reaction [Thyroxine inhibits the reaction [NCOR2 protein binds to and results in decreased activity of THRB protein]]]; SRC inhibits the reaction [bisphenol A inhibits the reaction [Thyroxine inhibits the reaction [NCOR1 protein binds to and results in decreased activity of THRB protein]]]; SRC inhibits the reaction [bisphenol A inhibits the reaction [Thyroxine inhibits the reaction [NCOR2 protein binds to and results in decreased activity of THRB protein]]]; tetraiodothyroacetic acid inhibits the reaction [Thyroxine inhibits the reaction [THRB protein binds to NCOR1 protein]]; tetraiodothyroacetic acid inhibits the reaction [Thyroxine inhibits the reaction [THRB protein binds to NCOR2 protein]]; Thyroxine inhibits the reaction [NCOR1 protein binds to and results in decreased activity of THRB protein]; Thyroxine inhibits the reaction [THRB protein binds to NCOR1 protein]; Thyroxine inhibits the reaction [THRB protein binds to NCOR2 protein]; Thyroxine inhibits the reaction [Triiodothyronine binds to THRB protein]; Thyroxine promotes the reaction [THRB protein binds to NCOA2 protein]
Thyroxine results in decreased expression of THRB mRNA
Thyroxine results in increased expression of THRB mRNA
[bisphenol A co-treated with Estradiol co-treated with Thyroxine] results in increased expression of THRB mRNA; [bisphenol A co-treated with Thyroxine] results in increased expression of THRB mRNA
Thyroxine results in increased activity of THRB protein
Thyroxine binds to THRB protein

PMID:18584933 PMID:19457453 PMID:22227104 PMID:23112079 PMID:23402801 More...

NCBI chr15:7,685,180...8,031,920
Ensembl chr15:7,685,180...7,882,916

G

tumor necrosis factor

increases expression
decreases expression
multiple interactions

Thyroxine results in increased expression of TNF mRNA
Thyroxine results in decreased expression of TNF mRNA
Thyroxine inhibits the reaction [Propylthiouracil results in increased expression of TNF protein]

PMID:23935926 PMID:24534949 PMID:34047416

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

tumor protein p53

affects localization
multiple interactions

Thyroxine affects the localization of TP53 protein modified form
tetraiodothyroacetic acid inhibits the reaction [Thyroxine affects the localization of TP53 protein modified form]

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

G

thyroid peroxidase

multiple interactions

[Propylthiouracil results in decreased activity of TPO protein] which results in decreased chemical synthesis of and results in decreased abundance of Thyroxine

NCBI chr 6:46,698,402...46,768,199
Ensembl chr 6:46,698,414...46,768,199

G

transient receptor potential cation channel, subfamily M, member 7

decreases abundance

TRPM7 gene mutant form results in decreased abundance of Thyroxine

NCBI chr 3:114,046,258...114,134,799
Ensembl chr 3:114,046,258...114,135,190

G

thyroid stimulating hormone subunit beta

multiple interactions
decreases expression

Clofibrate inhibits the reaction [Thyroxine results in decreased expression of TSHB protein]; Thyroxine inhibits the reaction [lead acetate results in decreased expression of TSHB protein]; Thyroxine inhibits the reaction [pexacerfont results in increased expression of TSHB protein]; Thyroxine inhibits the reaction [Propylthiouracil results in increased expression of TSHB protein]
Thyroxine results in decreased expression of TSHB mRNA

PMID:18219302 PMID:21871911 PMID:27420076 PMID:33340518 PMID:34047416

NCBI chr 2:190,224,676...190,229,559
Ensembl chr 2:190,224,676...190,229,559

G

thyroid stimulating hormone receptor

decreases activity

Thyroxine results in decreased activity of TSHR protein

NCBI chr 6:110,341,585...110,475,297
Ensembl chr 6:110,341,581...110,474,538

G

transthyretin

multiple interactions
affects binding

2,2',3',4,4',5-hexachlorobiphenyl inhibits the reaction [Thyroxine binds to TTR protein]; 2,2',3,3',4,4',5-heptachlorobiphenyl inhibits the reaction [Thyroxine binds to TTR protein]; 2,2',4,4'-tetrabromodiphenyl ether analog inhibits the reaction [Thyroxine binds to TTR protein]; 2,2',4,4'-tetrabromodiphenyl ether inhibits the reaction [Thyroxine binds to TTR protein]; 2,2',4,5'-tetrabromodiphenyl ether metabolite inhibits the reaction [Thyroxine binds to TTR protein]; 2,4,5,2',4',5'-hexachlorobiphenyl inhibits the reaction [Thyroxine binds to TTR protein]; 3,5-dichlorobiphenyl metabolite inhibits the reaction [Thyroxine binds to TTR protein]; 4-nonylphenol inhibits the reaction [Thyroxine binds to TTR protein]; bisphenol A inhibits the reaction [Thyroxine binds to TTR protein]; Diethylstilbestrol inhibits the reaction [Thyroxine binds to TTR protein]; Flame Retardants analog inhibits the reaction [Thyroxine binds to TTR protein]; Flame Retardants inhibits the reaction [Thyroxine binds to TTR protein]; Halogenated Diphenyl Ethers analog inhibits the reaction [Thyroxine binds to TTR protein]; PCB 180 inhibits the reaction [Thyroxine binds to TTR protein]; pentabromophenol inhibits the reaction [Thyroxine binds to TTR protein]; Pentachlorophenol inhibits the reaction [Thyroxine binds to TTR protein]; perfluoro-n-heptanoic acid affects the reaction [Thyroxine binds to TTR protein]; perfluoro-n-nonanoic acid affects the reaction [Thyroxine binds to TTR protein]; perfluorobutanesulfonic acid affects the reaction [Thyroxine binds to TTR protein]; perfluorobutyric acid affects the reaction [Thyroxine binds to TTR protein]; perfluorodecanoic acid affects the reaction [Thyroxine binds to TTR protein]; perfluorododecanoic acid affects the reaction [Thyroxine binds to TTR protein]; perfluorohexanoic acid affects the reaction [Thyroxine binds to TTR protein]; perfluorooctane sulfonic acid affects the reaction [Thyroxine binds to TTR protein]; perfluorooctane sulfonic acid inhibits the reaction [Thyroxine binds to TTR protein]; perfluorooctanoic acid affects the reaction [Thyroxine binds to TTR protein]; perfluorooctanoic acid inhibits the reaction [Thyroxine binds to TTR protein]; perfluoroundecanoic acid affects the reaction [Thyroxine binds to TTR protein]; Polychlorinated Biphenyls analog inhibits the reaction [Thyroxine binds to TTR protein]; T-2 Toxin inhibits the reaction [Thyroxine binds to TTR protein]; tetrabromobisphenol A inhibits the reaction [Thyroxine binds to TTR protein]; tetrachlorodian inhibits the reaction [Thyroxine binds to TTR protein]; Thyroxine inhibits the reaction [1-anilino-8-naphthalenesulfonate binds to TTR protein]; Wastewater inhibits the reaction [Thyroxine binds to TTR protein]
2,2',4,4'-tetrabromodiphenyl ether inhibits the reaction [Thyroxine binds to TTR protein]; 2,2',4,4'-tetrabromodiphenyl ether metabolite inhibits the reaction [Thyroxine binds to TTR protein]

PMID:10631123 PMID:10869457 PMID:16478101 PMID:16601080 PMID:18161906 More...

NCBI chr18:11,941,791...11,951,008
Ensembl chr18:11,943,789...11,951,008

G

uncoupling protein 2

multiple interactions

Thyroxine promotes the reaction [darglitazone results in increased expression of UCP2 mRNA]

NCBI chr 1:154,839,242...154,845,612
Ensembl chr 1:154,839,209...154,845,611

G

UDP glucuronosyltransferase family 1 member A1

increases expression

Thyroxine results in increased expression of UGT1A1 mRNA

NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465

G

UDP glycosyltransferase 1 family, polypeptide A3

increases expression

Thyroxine results in increased expression of UGT1A5 mRNA

NCBI chr 9:88,780,328...88,808,465
Ensembl chr 9:88,713,184...88,808,465

G

UDP glucuronosyltransferase 1 family, polypeptide A7C

increases expression

Thyroxine results in increased expression of UGT1A7 mRNA

NCBI chr 9:88,739,577...88,808,465
Ensembl chr 9:88,713,184...88,808,465

G

UDP glucuronosyltransferase family 1 member A9

multiple interactions

[Clofibrate co-treated with Thyroxine] results in increased activity of UGT1A9 protein

NCBI chr 9:88,696,981...88,808,465
Ensembl chr 9:88,713,184...88,808,465

G

vascular endothelial growth factor A

multiple interactions
increases expression
affects expression

Thyroxine inhibits the reaction [Propylthiouracil results in increased expression of VEGFA protein]
Thyroxine results in increased expression of VEGFA mRNA
Thyroxine affects the expression of VEGFA protein

PMID:25298361 PMID:25499719 PMID:35101570

NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641

Term paths to the root

Path 1
Term	Annotations
CHEBI ontology	19898
role	19868
application	19714
NMR chemical shift reference compound	18086
ammonia	17885
organic amino compound	17885
amino acid	16072
non-proteinogenic amino acid	3998
haloamino acid	459
bromoamino acid +	0
chloroamino acid +	0
fluoroamino acid +	3
iodoamino acid +	457
Path 2
Term	Annotations
CHEBI ontology	19898
subatomic particle	19896
composite particle	19896
hadron	19896
baryon	19896
nucleon	19896
atomic nucleus	19896
atom	19896
main group element atom	19835
main group molecular entity	19835
s-block molecular entity	19670
hydrogen molecular entity	19651
hydrides	19158
inorganic hydride	18176
pnictogen hydride	18166
nitrogen hydride	18079
azane	17886
ammonia	17885
organic amino compound	17885
amino acid	16072
non-proteinogenic amino acid	3998
haloamino acid	459
bromoamino acid +	0
chloroamino acid +	0
fluoroamino acid +	3
iodoamino acid +	457

paths to the root